<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2025.1536446</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>IFIT2-induced transcriptomic changes in <italic>Mycobacterium tuberculosis</italic> infected macrophages</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Manful</surname>
<given-names>Ewura-Esi</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2862567"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pietersen</surname>
<given-names>Ray-Dean</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Baker</surname>
<given-names>Bienyameen</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/551960"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African
Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Natarajaseenivasan Kalimuthusamy, Regional Medical Research Centre (ICMR), India</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Virtu Solano-Collado, University of Aberdeen, United Kingdom</p>
<p>Kangjam Rekha Devi, Regional Medical Research Centre (ICMR), India</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Ewura-Esi Manful, <email xlink:href="mailto:emanful1999@gmail.com">emanful1999@gmail.com</email>; Bienyameen Baker, <email xlink:href="mailto:brubaker@sun.ac.za">brubaker@sun.ac.za</email>
</p>
</fn>
<fn fn-type="present-address" id="fn003">
<p>&#x2020;Present address: Ewura-Esi Manful, Bioinformatics and Genomics, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, United States</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1536446</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>11</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>01</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Manful, Pietersen and Baker</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Manful, Pietersen and Baker</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Interferon-induced protein with tetratricopeptide repeat 2 (IFIT2) is known for its antiviral activity and has recently been implicated in the defense against <italic>Mycobacterium tuberculosis (M. tb).</italic> This study employed global transcriptomics to investigate the downstream effects of IFIT2 induction in THP-1 macrophages infected with R179 <italic>M. tb</italic>, aiming to elucidate its role and downstream contributing factors that aid it in intracellular <italic>M. tb</italic> killing. Using a vector-based overexpression approach, IFIT2 expression was induced in THP-1 cells infected with R179 <italic>M. tb</italic>, followed by RNA extraction 12 hours post-infection and AmpliSeq-based targeted transcriptome sequencing. Bioinformatics analysis identified 282 differentially expressed genes (DEGs), of which 189 were upregulated and 90 were downregulated (FDR &lt;0.05). Filtering for highly significant DEGs (|log<sub>2</sub>(fold change) | &gt; 1.5) yielded 70 genes, predominantly upregulated, with functional enrichment in pathways such as defense response to viruses and cytokine-mediated signaling. Signaling pathway impact analysis highlighted pathway activation and inhibition of the tuberculosis (TB) pathway. RT-qPCR validation confirmed the upregulation of selected DEGs (ISG15, CMPK2, RSAD2, IFI44L, IFI44), corroborating the AmpliSeq data. This study provides comprehensive insights into the transcriptomic profile induced by IFIT2 in TB, revealing critical downstream contributors and pathways that underpin IFIT2&#x2019;s ability to combat <italic>M. tb</italic> infection.</p>
</abstract>
<kwd-group>
<kwd>IFIT2</kwd>
<kwd>macrophages</kwd>
<kwd>tuberculosis</kwd>
<kwd>transcriptomics</kwd>
<kwd>gene expression</kwd>
<kwd>host-pathogen interaction</kwd>
</kwd-group>
<counts>
<fig-count count="8"/>
<table-count count="9"/>
<equation-count count="0"/>
<ref-count count="58"/>
<page-count count="20"/>
<word-count count="9835"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Bacteria and Host</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Tuberculosis (TB), caused by <italic>Mycobacterium tuberculosis</italic> (<italic>M. tb</italic>) is a global health issue that claims millions of lives every year. According to estimates from WHO, 10.8 million people worldwide developed TB in 2023 with 1.25 million deaths which is a slight increase from 10.7 million cases of TB and a decline from 1.3 million deaths in 2022 (<xref ref-type="bibr" rid="B50">WHO, 2024</xref>) Despite several interventions made in the treatment strategies for TB, the emergence of drug-resistant strains is on the rise with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains becoming most common, suggesting the need for new therapeutic approaches. Therefore, targeting host genes as potential host-directed therapies (HDTs) are currently gaining traction as a rational approach for improved TB therapy because of the unlikelihood of host resistance development (<xref ref-type="bibr" rid="B37">Palucci and Delogu, 2018</xref>). HDTs are a class of therapeutic agents that target the host immune system by improving their ability to fight infections rather than directly attacking the pathogen causing the disease (<xref ref-type="bibr" rid="B37">Palucci and Delogu, 2018</xref>).</p>
<p>During the host immune response to viruses, interferons (IFN) coordinate a strong host immune response by activating over 300 interferon-stimulated genes (ISGs) (<xref ref-type="bibr" rid="B43">Schoggins, 2018</xref>). These ISGs encode a variety of proteins that impede several phases of the viral replication cycle, including entry into the host cells, protein translation, replication, virus particle assembly, and propagation (<xref ref-type="bibr" rid="B12">Diamond and Farzan, 2013</xref>). The transcription of hundreds of ISGs downstream of IFN signaling has also been studied as an important factor for efficient host defense (<xref ref-type="bibr" rid="B43">Schoggins, 2018</xref>). IFNs are known to influence the host immune response to <italic>M. tb</italic> infection (<xref ref-type="bibr" rid="B14">Donovan et&#xa0;al., 2017</xref>), in addition to eliciting antiviral responses. They have been widely used in combination with antimicrobial drugs to treat patients with TB and have been shown to have a wide range of effects on <italic>M. tb</italic> infection. For example, Type I IFNs have been shown to enhance <italic>M. tb</italic> infection in the vast majority of cases, whereas IFN-&#x3b3; (gamma) has been shown to protect the host against <italic>M. tb</italic> infection (<xref ref-type="bibr" rid="B47">Travar et&#xa0;al., 2016</xref>). Among the most potently induced ISGs are the interferon-induced protein with tetratricopeptide repeats (IFITs).</p>
<p>IFIT family members are known for their antiviral activity. They are known to prevent viral replication by binding to and controlling viral proteins and RNAs (<xref ref-type="bibr" rid="B34">Mears and Sweeney, 2018</xref>). IFIT genes code for a group of proteins that are activated by IFN, viral infection, or pathogen-associated molecular pattern (PAMP) recognition. They have molecular weights ranging between 47 and 72kDa and they are conserved in all vertebrates that have coevolved with the IFN system during the evolution of the adaptive immune system. In humans, four members of the IFITs family have been identified: IFIT1 (ISG56), IFIT2 (ISG54), IFIT3 (ISG60), and IFIT5 (ISG58), all of which are found on chromosome 10q23 (<xref ref-type="bibr" rid="B34">Mears and Sweeney, 2018</xref>). Despite their roles in the defense against viruses, their roles and relationships in macrophages and other immune cells involved in the fight against <italic>M. tb</italic> have not yet been established. However, a previous study on the transcriptome profile of human monocyte-derived macrophages infected with both pathogenic and non-pathogenic mycobacteria identified the IFITs protein family as the top upregulated genes involved in the killing of mycobacteria (<xref ref-type="bibr" rid="B30">Madhvi et&#xa0;al., 2022</xref>). Additionally, the expression levels of IFIT genes were found to be higher in individuals with latent TB infection than in those with active TB, suggesting their potential role in controlling TB infection (<xref ref-type="bibr" rid="B30">Madhvi et&#xa0;al., 2022</xref>). To explore the involvement of IFIT genes in TB infection, their expression was stimulated to assess their impact on mycobacterial growth. The results showed that overexpression (knock-up) of IFITs led to a decrease in mycobacterial growth by approximately 48%, whereas gene knockdown resulted in a 78% increase in mycobacterial growth (<xref ref-type="bibr" rid="B30">Madhvi et&#xa0;al., 2022</xref>).</p>
<p>Emerging research has highlighted the involvement of IFIT genes in cancer growth and metastasis, revealing their opposing oncogenic functions. This is a crucial consideration when evaluating IFITs as potential therapeutic targets for TB. Specifically, IFIT1, IFIT3, and IFIT5 have been shown to enhance cancer cell growth (<xref ref-type="bibr" rid="B38">Pidugu et&#xa0;al., 2019</xref>), making them less desirable for further investigation regarding their roles in mycobacterial killing. Conversely, IFIT2 has been identified as a tumor suppressor gene and numerous studies have demonstrated that its knockdown significantly increases cancer cell proliferation in various tumors (<xref ref-type="bibr" rid="B38">Pidugu et&#xa0;al., 2019</xref>). This suggests a potentially positive prognosis for patients with cancer undergoing TB treatment that targets IFIT2. Moreover, a link between TB and cancer has been implicated in several studies (<xref ref-type="bibr" rid="B55">Yu et&#xa0;al., 2008</xref>; <xref ref-type="bibr" rid="B52">Wu et&#xa0;al., 2011</xref>; <xref ref-type="bibr" rid="B19">Heuvers et&#xa0;al., 2012</xref>), further underscoring the importance of carefully selecting IFIT genes for TB therapeutic development.</p>
<p>Considering the well-documented antiviral functions of IFIT2, its role in TB infection and mechanisms of action remain poorly understood. Understanding the downstream effects of IFIT2 expression in macrophages could provide new insights into host defense mechanisms against <italic>M. tb</italic> and identify potential targets for therapeutic interventions. Therefore, our study aimed to elucidate the downstream contributors to IFIT2&#x2019;s antimycobacterial effects in macrophages infected with mycobacteria. Using global transcriptomics, our findings revealed key differentially expressed genes (DEGs) upregulated downstream of IFIT2 induction. The increased expression of chemokines, cytokines, and other interferon-stimulated genes (ISGs) demonstrated antimycobacterial killing effects and involvement in mycobacterial infections. These diverse gene expression profiles were associated with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, including responses to viruses, innate immune responses, and chemokine signaling pathways. Additionally, we observed from our Signaling Impact analysis that the tuberculosis pathway was inhibited confirming the downstream contributing factors to the antimycobacterial activity of IFIT2.</p>
<p>The insights gained from this study will advance our understanding of the molecular mechanisms by which IFIT2 contributes to the intracellular killing of <italic>M. tb</italic>. By delineating the transcriptomic profile associated with IFIT2 induction in TB, we aimed to identify potential therapeutic targets and pathways that could be leveraged to improve TB treatment strategies. Ultimately, this study seeks to contribute to the development of more effective interventions for TB, addressing the critical need for global health.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Macrophage and mycobacteria cell culture</title>
<p>THP-1 cells, which are a human monocytic cell line, were cultured in a T25 cell culture flask in Roswell Park Memorial Institute Medium (RPMI)-1640 (LTC Tech, 21875034) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (LTC Tech, 10493106), incubated under 5% CO<sub>2</sub> and at 37&#xb0;C and transferred after 3 days to a T75 culture flask for further expansion inside a biosafety level 2 laboratory (BSL2).</p>
<p>The clinical multi drug-resistant (MDR) R179 <italic>M. tb</italic> strain and the <italic>M. Bovis</italic> BCG strain were cultured separately in Middlebrook 7H9 (Sigma-Aldrich, M0178) with 10% OADC (Albumin, Dextrose, Oleic Acid, Catalase and Sodium Chloride) (Becton Dickinson, 212240) and 0.5% glycerol (Merck Millipore, Germany, G5516-1L) without Tween 80, as this detergent is known to affect macrophage uptake and the host response to <italic>M. tb</italic> (<xref ref-type="bibr" rid="B26">Leisching et&#xa0;al., 2016b</xref>),. The bacteria were cultured as previously described. Briefly, a starter culture was set up in T25 cell culture flask at a volume of 10 ml and incubated for 2-3 days at 37&#xb0;C until an optical density (OD) of less than 0.4 was reached. Subcultures, also in T25 cell culture flasks, were grown to a maximum OD of 0.4 and stored at -80&#xb0;C until needed.</p>
</sec>
<sec id="s2_2">
<title>Macrophage infection with mycobacteria</title>
<p>For infection experiments, THP-1 cells were seeded in 24-well plates (CELLSTAR<sup>&#xae;</sup>, P1PLA044C-000048) at 1 &#xd7; 10<sup>5</sup> cells/well with Phorbol 12-Myristate 13-Acetate (PMA) (Sigma Aldrich, USA) at a final concentration of 100 nM in growth medium (RPMI) supplemented with 10% FBS and incubated for 72 h to differentiate THP-1 cells into macrophage cells. The differentiated THP-1 (dTHP-1) cells were then transferred to a CO<sub>2</sub> incubator in a biosafety level 3 (BSL3) laboratory and infected.</p>
<p>Mycobacterial culture stocks (1ml) were thawed, and clumps were broken and loosened by pipetting ten times with a 1000 &#x3bc;l pipette. Subsequently, the mycobacterial culture was syringed 10 times through a 25 gauge (G25) needle to further break the clumps and obtain single bacteria (<xref ref-type="bibr" rid="B25">Leisching et&#xa0;al., 2016a</xref>). This technique is referred to as the syringe-settle-filtrate (SSF) method (<xref ref-type="bibr" rid="B31">Madhvi et&#xa0;al., 2020</xref>). The vial was immediately allowed to stand for 30 s to allow the large clumps to settle after syringing. The top 750 &#x3bc;l was carefully removed, mixed with 4.25 ml macrophage growth medium and the 5 ml bacterial suspension filtered through a 5.0 &#x3bc;m pore size filter (Merck Millipore, Germany). Filtering through a 5.0 &#x3bc;m pore size filter eliminates all large clumps, leaving only small clumps of approximately 2&#x2013;3 bacteria. More than 90% of the filtered bacteria have been determined to be single (<xref ref-type="bibr" rid="B25">Leisching et&#xa0;al., 2016a</xref>). The exact same method (SSF) was used prior to infection to determine the titer of the filtered bacteria. The required volume of filtered bacteria was mixed with growth medium and added to the dTHP-1 cells to give a Multiplicity of Infection (MOI) of one. The 24-well plates were incubated for 4 h to allow for bacterial uptake.</p>
<p>To remove extracellular mycobacteria, the infected dTHP-1 cells were washed three times with 800 &#x3bc;l 1x Phosphate Buffer saline (PBS) (LTC Tech, 14190144) and prepared for vector-based overexpression of the target gene (IFIT2) by adding 250 &#x3bc;l of growth medium per well. Cells that served as a negative control for vector treatment, received 300 &#x3bc;l of growth medium per well. Uninfected THP-1 cells were used as controls. For basal measurements, infected and uninfected cells were collected 4 h post-infection to capture baseline gene expression prior to vector-based treatments.</p>
</sec>
<sec id="s2_3">
<title>Transfection of THP-1 for vector-based overexpression of target gene (IFIT2)</title>
<p>Plasmid transfection was performed using Mission siRNA liposome-based transfection reagent (Sigma-Aldrich, S1452). The transfection of the IFIT2 gene into THP-1 cells for its overexpression (knock-up) was done in 24 well plates with 1 &#xd7; 10<sup>5</sup> cells per well in 250 &#x3bc;l of growth medium. For each well containing THP-1 cells (infected or uninfected) that had to be treated with vector, 50 &#x3bc;l of transfection Master Mix was added to the 250 &#x3bc;l of growth medium already present in the wells. Transfection Master Mix, per well, consisted of 1 &#x3bc;l of transfection reagent, 0.3 &#x3bc;l (equating to 60 ng at the final dilution) of plasmid DNA vector and 48.7 &#x3bc;l of Dulbecco&#x2019;s Modified Eagle&#x2019;s Medium (DMEM) which was mixed, vortexed and allowed to stand at room temperature for 15 minutes. The final volume in each well was 300 &#x3bc;l.</p>
<p>The plasmid DNA vectors used included IFIT2 with a FLAG tag placed at the N-terminus [GenScript, SC1200_OHu31069C], IFIT2 with a FLAG tag placed at the C-terminus (GenScript, SC1200_OHu31069D), IFIT2 with no FLAG tag (GenScript, SC1200_OHu31069E), a non-specific gene vector, Creatinine Kinase (CKB) (GenScript, OHu09573), and Empty Vector (GenScript, SC1822). The pcDNA 3.1+C/-(K)-DYK plasmid was used to generate each vector. Uninfected THP-1 cells, mycobacteria-infected THP-1 cells, uninfected-IFIT2 induced THP-1 cells, mycobacteria-infected CKB-induced THP-1 cells, and mycobacteria-infected THP-1 cells transfected with the empty vector served as control samples. The cells were then incubated for 8 h at 37&#xb0;C in an incubator with 5% CO<sub>2</sub>.</p>
</sec>
<sec id="s2_4">
<title>RNA extraction</title>
<p>Infected THP-1 cells after 4 h of uptake (4 h post infection) and uninfected THP-1 cells were prepared for RNA extraction after washing thrice with PBS. RNA was extracted immediately after collecting the 4-hour uptake samples to accurately capture baseline gene expression. Total RNA from human macrophage-like cells was extracted using a kit (RNeasy Plus Mini Kit) according to the manufacturer&#x2019;s instructions. Extraction was also performed immediately following the 12 h infection period. Genomic DNA (gDNA) was removed by column filtration using the &#x201c;gDNA eliminator&#x201d; column included in the kit. For each experiment, the RNA quantity and quality were assessed using an Agilent 2100 Bioanalyzer. Only RNA samples with an RNA integrity number (RIN) &#x2265; 9 were used for AmpliSeq (Targeted Transcriptome Sequencing) and RT-qPCR experiments. Total RNA was extracted and frozen immediately at &#x2212;80&#xb0;C until use.</p>
</sec>
<sec id="s2_5">
<title>AmpliSeq (targeted transcriptome sequencing)</title>
<p>AmpliSeq, a targeted transcriptome sequencing technique, was performed at the Central Analytical Facilities (CAF) at Stellenbosch University, South Africa. The Ion AmpliSeq&#x2122; Transcriptome Human Gene Expression Panel Chef-Ready Kit was used to prepare Ion AmpliSeq transcriptome libraries on the Ion Chef&#x2122; System according to the manufacturer&#x2019;s protocol. 10 ng total RNA was reverse transcribed using the SuperScript&#x2122; VILO&#x2122; cDNA Synthesis Kit with incubation at 42&#xb0;C for 30 minutes and enzymatic inactivation at 85&#xb0;C for 5 minutes on a SimpliAmp&#x2122; Thermal Cycler (Thermo Fisher Scientific). The reverse-transcribed samples were loaded onto the Ion Chef&#x2122; System for library construction, with thirteen amplification cycles consisting of 16 minutes of annealing and extension for amplification of the primer targets. The libraries were diluted to a target concentration of 60 pM (picomolar) for template preparation using the Ion 540 Chef Kit (Thermo Fisher Scientific). 25 &#x3bc;l of diluted, pooled barcoded library were loaded onto the Ion Chef liquid handler for template preparation and enrichment using Ion 540&#x2122; Chef Reagents, Solutions and Supplies according to the protocol, MAN0010851 F.0. The enriched spherical ion particles were loaded onto an Ion 540 chip. Massively parallel sequencing was performed on the Ion Torrent&#x2122; GeneStudio&#x2122; S5 Prime System using Sequencing Solutions and Reagents, according to the protocol MAN0010851 F.0. Flow space calibration and base-caller analysis were performed using standard analysis parameters in Torrent Suite Version 5.18.1 Software. The reads were quality trimmed during the base-calling step using a moving window of 30 base pairs and a cutoff quality value (QV) of 15. Mapping was performed using the Torrent Mapping Alignment Program (TMAP) included in Torrent Suit software V5.18.1. Reads were mapped to the hg19_AmpliSeq_Transcriptome_v1.1 reference genome, and only reads with an alignment length of 17 or more were retained. Read counts were generated using the AmpliSeq RNA plugin.</p>
</sec>
<sec id="s2_6">
<title>Identification of differentially expressed genes</title>
<p>The analysis of differentially expressed genes (DEGs) was performed in R version 4.3.1, using the DESeq2 R package, which uses a negative binomial distribution model (<xref ref-type="bibr" rid="B28">Love et&#xa0;al., 2014</xref>). The Benjamini-Hochberg method was used to correct for multiple testing. P-adjusted (or false discovery rate) values less than 0.05 and absolute log<sub>2</sub>(fold change) &gt; 1.5 were used to screen out the highly significant DEGs.</p>
</sec>
<sec id="s2_7">
<title>Functional analysis</title>
<p>The top 70 genes with log<sub>2</sub>(fold change) &gt;1.5 extracted were selected and GO functional analysis and KEGG pathway enrichment analysis (P&#x2009;&lt;&#x2009;0.05) were performed using the clusterProfiler package (<xref ref-type="bibr" rid="B46">Tianzhi. et&#xa0;al., 2021</xref>) in R software.</p>
<p>Functional analysis was performed by first performing over-representation analysis using Gene Ontology (GO) terms to identify which GO terms were overrepresented or underrepresented in the DEGs. The GO terms were grouped into biological processes, molecular functions, and cellular components. The clusterProfiler R package was used for over-representation analysis by performing statistical analyses using hypergeometric testing (<xref ref-type="bibr" rid="B46">Tianzhi. et&#xa0;al., 2021</xref>). All genes tested for differential gene analysis were used as background genes. Genes with p-adjusted values less than 0.05, and log<sub>2</sub>(fold change) &gt; 1.5 or &lt; &#x2013;1.5, were used as significant gene lists. Bar plots were used to visualize over-representative GO terms in the differentially expressed genes. Functional class scoring analysis was performed using gene set enrichment analysis (GSEA) and gene sets from the Kyoto Encyclopedia of Genes and Genomes (KEGG). GSEA evaluates whether gene sets for certain biological pathways are enriched in the larger absolute log<sub>2</sub>(fold changes) by performing analysis using the log<sub>2</sub> (fold changes) generated by DEGs analysis from DESeq2 for each gene. The clusterProfiler R package and Pathview tools were used to perform gene set enrichment and pathway analyses in R Studio. Here, the coordinated differential expression of a group of genes that share functional similarities was tested instead of single genes. The NA values and duplicates were removed prior to the analysis. The Pathview R package was used to transform the KEGG pathway data from clusterProfiler into pathway images. Finally, pathway topology analysis was performed using the Signaling Pathway Impact Analysis (SPIA) tool. The SPIA R package in R was used to include all substantial information that was not obtained from the GO and GSEA analysis (<xref ref-type="bibr" rid="B45">Tarca et&#xa0;al., 2009</xref>).</p>
</sec>
<sec id="s2_8">
<title>Construction of a protein&#x2013;protein interaction network</title>
<p>To investigate the relationships between the highly significant DEGs extracted with log<sub>2</sub>(fold change) &gt; 1.5, protein-protein interaction networks were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database version 12.0 with default parameters.</p>
</sec>
<sec id="s2_9">
<title>RT-qPCR</title>
<p>To validate the transcriptomic data, we selected five key DEGs and performed RT-qPCR. Good quality RNA (RIN&gt;9, 0.8&#xb5;g) was converted to cDNA using the Quantitect<sup>&#xae;</sup> Reverse Transcription Kit. To ensure the removal of genomic DNA, &#x201c;gDNA wipe-out buffer&#x201d; was used. RT-qPCR amplification was performed using a LightCycler 96 system (Roche, Germany). The LightCycler<sup>&#xae;</sup> 480 SYBR Green I Master and QuantiTect<sup>&#xae;</sup> primers were used.</p>
<p>Hs-GAPDH and Hs-UBC were selected as reference genes. The amplification process involved 45 cycles at 95&#xb0;C for 10s followed, 60&#xb0;C for 10s and finally 72&#xb0;C for 10s. Gene expression fold-changes were computed for infected macrophages without treatment and infected macrophages with treatment using calibrated, normalized relative quantities using the equation N =N<sub>0</sub>&#xd7;2<sup>Cp</sup>. All RT-qPCRs were performed on RNA extracted from three separate experiments, with three technical replicates for each set of experiments. All biological replicates, a positive control, and a non-reverse transcription control were run in triplicate (along with the calibrator) according to MIQE Guidelines (<xref ref-type="bibr" rid="B10">Bustin et&#xa0;al., 2009</xref>).</p>
</sec>
<sec id="s2_10">
<title>Statistical analysis</title>
<p>Data generated from RT-qPCR were analyzed using Light Cycler 96 SW 1.1 software to obtain the relative mRNA expression. The relative mRNA expressions were further analyzed using One-Way ANOVA and Tukey&#x2019;s test for multiple test corrections to generate p-values and graphs in GraphPad Prism V8.</p>
<p>GraphPad Prism V8 was used to analyze the CFU count using One-Way ANOVA and Tukey&#x2019;s test for multiple test corrections to generate p-values and graphs.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Gene optimization for knock-up experiments using different vector constructs</title>
<p>In constructing plasmid vectors for overexpression analysis, DNA sequences of target genes are often altered to include tags for purification and detection purposes. Commonly used mammalian expression vectors, such as pcDNA3.1, can incorporate tags such as FLAG, Poly histidine tag (His-tag) and the glutathione S-transferase (<xref ref-type="bibr" rid="B8">Booth et&#xa0;al., 2018</xref>). This study used the FLAG tag for IFIT2 vector construction, which is advantageous due to its small size, hydrophilicity, and ease of detection (<xref ref-type="bibr" rid="B53">Yadav et&#xa0;al., 2016</xref>). The positioning of tags can affect protein stability, activity, and structure, necessitating investigation to ensure functionality. Therefore, the current study evaluated the effects of FLAG tag positioning on IFIT2 expression and anti-mycobacterial activity against <italic>M. tb</italic> in THP-1 cells by comparing N-terminal FLAG, C-terminal FLAG, and no FLAG vector constructs. The anti-mycobacterial effects were evaluated by recording CFUs, and gene expression levels were measured using RT-qPCR.</p>
</sec>
<sec id="s3_2">
<title>Effect of FLAG tag positioning on IFIT2 expression and anti-mycobacterial activity</title>
<p>The positioning of the FLAG tag significantly influenced IFIT2 expression levels and
anti-mycobacterial activity. The C-Flagged IFIT2 vector exhibited the lowest gene expression and highest CFU counts against <italic>M. bovis</italic> BCG (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1A, B</bold>
</xref>), indicating reduced anti-mycobacterial activity. In contrast, both N-Flagged and No-Flag IFIT2 vectors demonstrated higher expression levels and significantly lower CFU counts, suggesting improved anti-mycobacterial activity. Interestingly, the empty vector control also showed some anti-mycobacterial effects and IFIT2 expression, likely due to a non-specific immune response. However, the anti-mycobacterial activity of the empty vector-transfected control group was lower than that of the N-Flagged and No-Flag vectors though the observed difference were not statistically significant.</p>
<p>To explore this further, we tested the N-Flagged and No-Flag constructs using the multi-drug-resistant R179 <italic>M. tb</italic> strain, which is closer to real-life TB infections. A non-specific gene vector, Creatine Kinase (CKB), was included as a control, based on previous data showing unchanged expression in infected macrophages. The results showed that the N-Flagged IFIT2 vector had the lowest CFUs, and higher IFIT2 gene expression compared to the No-Flag vector (<xref ref-type="supplementary-material" rid="SF2">
<bold>Supplementary Figures&#xa0;2A, B</bold>
</xref>). Interestingly, both the empty vector and CKB also showed some anti-mycobacterial activity and IFIT2 expression. Collectively, these results highlight the N-Flagged IFIT2 construct as the most effective and suitable for further high throughput studies, while the C-Flagged construct was deemed unsuitable due to poor antimycobacterial activity.</p>
</sec>
<sec id="s3_3">
<title>General analysis of comparative transcriptome</title>
<p>RNA-seq analysis of the samples from uninfected cells, uninfected cells with IFIT2 treatment, infected cells with treatment (IFIT2, Empty vector, and non-specific gene vector CKB), and infected cells without treatment yielded an average of 63 million reads aligned to the hg19 AmpliSeq Transcriptome v1.1. Principal Component Analysis (PCA) showed distinct clustering of the different groups &#x2013; uninfected from infected cells and treated from untreated cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Infected, untreated THP-1 cells served as the reference for all treatments. The pairwise comparisons included IFIT2-transfected <italic>M. tb</italic>-infected THP-1 cells vs. <italic>M. tb</italic>-infected THP-1 cells only, empty vector-transfected <italic>M. tb</italic>-infected THP-1 cells vs. <italic>M. tb</italic>-infected THP-1 cells only, and CKB-transfected <italic>M. tb</italic>-infected THP-1 cells vs. <italic>M. tb</italic>-infected THP-1 cells only. Venn diagrams of the differentially expressed genes from the three treatment groups revealed both shared and unique genes in each treatment group (<xref ref-type="supplementary-material" rid="SF7">
<bold>Supplementary Figure&#xa0;7</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>PCA plot illustrating sample grouping by condition and treatment. This plot shows how samples cluster based on their differences, with PC1 explaining 41% of the variance and PC2 explaining 28%. Samples are colored by condition (red for infected, blue for uninfected) and use different shapes to represent treatments (CKB, Empty Vector, IFIT2, and Untreated). The clustering clearly separates infected from uninfected samples and highlights differences between treatments, reflecting distinct patterns in the data.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g001.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>Differential gene expression analysis and identification</title>
<p>Using R Studio and the DESeq2 R package, we conducted a thorough analysis to identify differentially expressed genes (DEGs) and compared all experimental treatments with the control groups. We employed a cutoff value of false discovery rate (FDR), also known as the p-adjusted value &lt; 0.05, to extract significant DEGs. An MA-plot was generated to visualize genome-wide transcriptome expression at 12h post-infection in the treated groups compared to that in the control groups (<xref ref-type="supplementary-material" rid="SF3">
<bold>Supplementary Figure&#xa0;3</bold>
</xref>). A total of 282 DEGs were identified, with 189 upregulated and 90 downregulated DEGs
observed in IFIT2-induced <italic>M. tb</italic>-infected THP-1 cells compared to those in <italic>M. tb</italic>-infected THP-1 cells only. Due to the anti-mycobacterial activity and <italic>IFIT2</italic> gene expression levels observed in the control (empty vector-transfected <italic>M. tb</italic>-infected THP-1 cells, and the non-specific gene (<italic>CKB</italic>)-transfected <italic>M. tb</italic>-infected THP-1 cells) in the preliminary (gene optimization) experiments, we sought to identify the DEGs expressed (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1</bold>
</xref>, <xref ref-type="supplementary-material" rid="SF2">
<bold>2</bold>
</xref>). For the Empty Vector, 194 DEGs were identified and compared to the <italic>M. tb</italic>-infected THP-1 cells only. Of these, 123 DEGs were upregulated and 71 DEGs were downregulated. In addition, 249 DEGs were identified for the non-specific gene vector CKB, of which 175 DEGs were upregulated and 74 DEGs were downregulated.</p>
<p>Volcano plots and heatmaps were used to provide detailed insights into the expression patterns of the DEGs. Hierarchical clustering of DEGs shown in the heatmap in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>, revealed distinct clustering patterns between the treatment and control groups, underscoring the reliability of the samples. We used the gene expression data from each sample to determine the distance between them and their correlations. As shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>, the treatment groups consistently formed separate clusters from those of the control groups, emphasizing the precision and reliability of the samples. Additionally, volcano plots in <xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3</bold>
</xref>, <xref ref-type="fig" rid="f4">
<bold>4</bold>
</xref> illustrate the top 30 significant gene expression changes downstream of IFIT2 and the Empty Vector, respectively.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Heatmap for all treatments groups vs controls showing hierarchical clustering of differentially expressed genes (DEGs) in all samples. The infected untreated (IU) control groups were compared to the different treatment groups; <bold>(A)</bold> IFIT2-transfected THP-1 infected with R179M.tb, <bold>(B)</bold> CKB-transfected THP-1 infected with R179M.tb, and <bold>(C)</bold> Empty vector-transfected THP-1 infected with R179M.tb. Each column represents a sample with three biological replicates and each row represents a gene. The color scale represents the relative gene expression levels, with blue indicating high expression (upregulation), brown indicating low expression (downregulation), and white indicating no expression. DEGs were identified by false rate discovery (p-adjusted value) of &lt; 0.05.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Volcano plot for the top 30 significant genes downstream of IFIT2 with an FDR&lt;0.05. The blue dots represent genes with an absolute log<sub>2</sub>(fold change) greater than 1.5. Orange dots denote genes with an absolute log<sub>2</sub>(fold change) of less than 1.5. All dots above the zero point are upregulated genes and the ones below the zero point are downregulated genes.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g003.tif"/>
</fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Volcano plot for Top 30 significant genes downstream of Empty vector with FDR&lt;0.05. The blue dots represent genes with an absolute log<sub>2</sub>(fold-change) greater than 1.5. Orange dots denote genes with an absolute log<sub>2</sub>(fold change) of less than 1.5. All dots above the zero point are upregulated genes and the ones below the zero point are downregulated genes. EV: Empty Vector.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g004.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Transcriptomic profile of <italic>IFIT2</italic>-induced <italic>M. tb</italic>-infected macrophages</title>
<p>We applied stringent filtering criteria to extract top-ranked significant DEGs, resulting in 70 (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) genes with an absolute log<sub>2</sub>(fold change) &gt; 1.5 and FDR &lt; 0.05, among which only two were downregulated. The top 30 significant DEGs are represented in a volcano plot (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>All significantly expressed genes with p. adjusted value (FDR) &lt; 0.05 &amp; |log<sub>2</sub>(fold change)| &gt; 1.5 downstream of <italic>IFIT2</italic> in <italic>M. tb</italic>-infected macrophages compared to control (infected macrophages only).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Gene</th>
<th valign="top" align="center">log<sub>2</sub>(fold change)</th>
<th valign="top" align="center">P value</th>
<th valign="top" align="center">P adjusted Value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">
<italic>IFIT2</italic>
</td>
<td valign="top" align="center">6.095364</td>
<td valign="top" align="center">1.12E-26</td>
<td valign="top" align="center">1.35E-22</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFIT1</italic>
</td>
<td valign="top" align="center">5.655365</td>
<td valign="top" align="center">5.00E-14</td>
<td valign="top" align="center">1.51E-10</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFIT3</italic>
</td>
<td valign="top" align="center">4.477372</td>
<td valign="top" align="center">4.49E-14</td>
<td valign="top" align="center">1.51E-10</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>HERC5</italic>
</td>
<td valign="top" align="center">5.198674</td>
<td valign="top" align="center">1.65E-12</td>
<td valign="top" align="center">4.00E-09</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CMPK2</italic>
</td>
<td valign="top" align="center">4.733145</td>
<td valign="top" align="center">7.17E-12</td>
<td valign="top" align="center">1.24E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>OASL</italic>
</td>
<td valign="top" align="center">5.389751</td>
<td valign="top" align="center">4.73E-11</td>
<td valign="top" align="center">6.36E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1F</italic>
</td>
<td valign="top" align="center">5.466841</td>
<td valign="top" align="center">5.93E-11</td>
<td valign="top" align="center">7.18E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PELI1</italic>
</td>
<td valign="top" align="center">1.709116</td>
<td valign="top" align="center">8.28E-11</td>
<td valign="top" align="center">8.43E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>RTP4</italic>
</td>
<td valign="top" align="center">3.161896</td>
<td valign="top" align="center">8.35E-11</td>
<td valign="top" align="center">8.43E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>HIVEP3</italic>
</td>
<td valign="top" align="center">-1.64719</td>
<td valign="top" align="center">1.00E-10</td>
<td valign="top" align="center">9.31E-08</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1E</italic>
</td>
<td valign="top" align="center">5.64155</td>
<td valign="top" align="center">1.38E-10</td>
<td valign="top" align="center">1.12E-07</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>USP18</italic>
</td>
<td valign="top" align="center">2.056305</td>
<td valign="top" align="center">7.19E-10</td>
<td valign="top" align="center">5.12E-07</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>DDX58</italic>
</td>
<td valign="top" align="center">3.458318</td>
<td valign="top" align="center">1.39E-09</td>
<td valign="top" align="center">9.35E-07</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT2P1</italic>
</td>
<td valign="top" align="center">4.24462</td>
<td valign="top" align="center">2.03E-09</td>
<td valign="top" align="center">1.29E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IRF1</italic>
</td>
<td valign="top" align="center">1.515355</td>
<td valign="top" align="center">2.52E-09</td>
<td valign="top" align="center">1.52E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>HELZ2</italic>
</td>
<td valign="top" align="center">1.922969</td>
<td valign="top" align="center">2.82E-09</td>
<td valign="top" align="center">1.62E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT2A</italic>
</td>
<td valign="top" align="center">4.311089</td>
<td valign="top" align="center">3.51E-09</td>
<td valign="top" align="center">1.93E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PPM1K</italic>
</td>
<td valign="top" align="center">1.985364</td>
<td valign="top" align="center">6.29E-09</td>
<td valign="top" align="center">3.04E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PLSCR1</italic>
</td>
<td valign="top" align="center">2.087734</td>
<td valign="top" align="center">1.00E-08</td>
<td valign="top" align="center">4.19E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SAMD9</italic>
</td>
<td valign="top" align="center">2.404955</td>
<td valign="top" align="center">9.91E-09</td>
<td valign="top" align="center">4.19E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1XP1</italic>
</td>
<td valign="top" align="center">4.793182</td>
<td valign="top" align="center">1.66E-08</td>
<td valign="top" align="center">6.22E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SDS</italic>
</td>
<td valign="top" align="center">2.432066</td>
<td valign="top" align="center">2.00E-08</td>
<td valign="top" align="center">7.11E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>RSAD2</italic>
</td>
<td valign="top" align="center">4.685321</td>
<td valign="top" align="center">5.08E-08</td>
<td valign="top" align="center">1.66E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TMEM140</italic>
</td>
<td valign="top" align="center">3.140736</td>
<td valign="top" align="center">1.01E-07</td>
<td valign="top" align="center">3.22E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>ATF4P3</italic>
</td>
<td valign="top" align="center">1.659223</td>
<td valign="top" align="center">1.15E-07</td>
<td valign="top" align="center">3.39E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>OAS1</italic>
</td>
<td valign="top" align="center">2.752892</td>
<td valign="top" align="center">1.13E-07</td>
<td valign="top" align="center">3.39E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>NADK</italic>
</td>
<td valign="top" align="center">1.981518</td>
<td valign="top" align="center">1.56E-07</td>
<td valign="top" align="center">4.51E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFIH1</italic>
</td>
<td valign="top" align="center">2.64276</td>
<td valign="top" align="center">2.17E-07</td>
<td valign="top" align="center">6.11E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CXCL10</italic>
</td>
<td valign="top" align="center">4.194844</td>
<td valign="top" align="center">3.55E-07</td>
<td valign="top" align="center">8.76E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>APOL6</italic>
</td>
<td valign="top" align="center">1.607034</td>
<td valign="top" align="center">4.14E-07</td>
<td valign="top" align="center">0.0001</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PARP14</italic>
</td>
<td valign="top" align="center">1.820307</td>
<td valign="top" align="center">4.33E-07</td>
<td valign="top" align="center">0.000103</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>EPSTI1</italic>
</td>
<td valign="top" align="center">2.868286</td>
<td valign="top" align="center">4.55E-07</td>
<td valign="top" align="center">0.000106</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>FAM84B</italic>
</td>
<td valign="top" align="center">1.71979</td>
<td valign="top" align="center">5.40E-07</td>
<td valign="top" align="center">0.000121</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFNB1</italic>
</td>
<td valign="top" align="center">5.566567</td>
<td valign="top" align="center">5.59E-07</td>
<td valign="top" align="center">0.000123</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>DTX3L</italic>
</td>
<td valign="top" align="center">1.635955</td>
<td valign="top" align="center">8.17E-07</td>
<td valign="top" align="center">0.00017</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MX1</italic>
</td>
<td valign="top" align="center">3.606722</td>
<td valign="top" align="center">9.87E-07</td>
<td valign="top" align="center">0.000199</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>GBP5</italic>
</td>
<td valign="top" align="center">3.431109</td>
<td valign="top" align="center">1.39E-06</td>
<td valign="top" align="center">0.000276</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PARP9</italic>
</td>
<td valign="top" align="center">1.924054</td>
<td valign="top" align="center">1.81E-06</td>
<td valign="top" align="center">0.000354</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MX2</italic>
</td>
<td valign="top" align="center">3.61166</td>
<td valign="top" align="center">2.48E-06</td>
<td valign="top" align="center">0.000454</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>XAF1</italic>
</td>
<td valign="top" align="center">2.949697</td>
<td valign="top" align="center">2.56E-06</td>
<td valign="top" align="center">0.000456</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TRIB3</italic>
</td>
<td valign="top" align="center">1.710137</td>
<td valign="top" align="center">3.15E-06</td>
<td valign="top" align="center">0.000526</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TRIM22</italic>
</td>
<td valign="top" align="center">3.081727</td>
<td valign="top" align="center">3.57E-06</td>
<td valign="top" align="center">0.000569</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>STC2</italic>
</td>
<td valign="top" align="center">1.678362</td>
<td valign="top" align="center">3.86E-06</td>
<td valign="top" align="center">0.000607</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CCL8</italic>
</td>
<td valign="top" align="center">2.875998</td>
<td valign="top" align="center">4.26E-06</td>
<td valign="top" align="center">0.000661</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>BATF3</italic>
</td>
<td valign="top" align="center">2.207363</td>
<td valign="top" align="center">4.78E-06</td>
<td valign="top" align="center">0.000714</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFI16</italic>
</td>
<td valign="top" align="center">2.199472</td>
<td valign="top" align="center">5.23E-06</td>
<td valign="top" align="center">0.000753</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CXCL11</italic>
</td>
<td valign="top" align="center">4.306407</td>
<td valign="top" align="center">1.02E-05</td>
<td valign="top" align="center">0.001283</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>ISG15</italic>
</td>
<td valign="top" align="center">2.139982</td>
<td valign="top" align="center">1.09E-05</td>
<td valign="top" align="center">0.001345</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>LZTS1</italic>
</td>
<td valign="top" align="center">-2.46576</td>
<td valign="top" align="center">1.50E-05</td>
<td valign="top" align="center">0.001733</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TNFSF13B</italic>
</td>
<td valign="top" align="center">3.412535</td>
<td valign="top" align="center">2.46E-05</td>
<td valign="top" align="center">0.002684</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>ISG20</italic>
</td>
<td valign="top" align="center">1.650762</td>
<td valign="top" align="center">2.64E-05</td>
<td valign="top" align="center">0.002849</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>NUPR1</italic>
</td>
<td valign="top" align="center">1.786633</td>
<td valign="top" align="center">2.68E-05</td>
<td valign="top" align="center">0.002871</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFI44</italic>
</td>
<td valign="top" align="center">2.516045</td>
<td valign="top" align="center">3.25E-05</td>
<td valign="top" align="center">0.003417</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>OAS2</italic>
</td>
<td valign="top" align="center">2.435235</td>
<td valign="top" align="center">3.49E-05</td>
<td valign="top" align="center">0.003607</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>GBP4</italic>
</td>
<td valign="top" align="center">2.569444</td>
<td valign="top" align="center">4.99E-05</td>
<td valign="top" align="center">0.004791</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TNFSF10</italic>
</td>
<td valign="top" align="center">3.079018</td>
<td valign="top" align="center">6.76E-05</td>
<td valign="top" align="center">0.00625</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TAGAP</italic>
</td>
<td valign="top" align="center">1.587024</td>
<td valign="top" align="center">7.87E-05</td>
<td valign="top" align="center">0.007103</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SP110</italic>
</td>
<td valign="top" align="center">2.087771</td>
<td valign="top" align="center">0.000106</td>
<td valign="top" align="center">0.008901</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MB21D2</italic>
</td>
<td valign="top" align="center">2.551266</td>
<td valign="top" align="center">0.000108</td>
<td valign="top" align="center">0.009043</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>C1orf115</italic>
</td>
<td valign="top" align="center">2.109667</td>
<td valign="top" align="center">0.000138</td>
<td valign="top" align="center">0.010842</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PROC</italic>
</td>
<td valign="top" align="center">1.713976</td>
<td valign="top" align="center">0.000185</td>
<td valign="top" align="center">0.012719</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFI44L</italic>
</td>
<td valign="top" align="center">2.642011</td>
<td valign="top" align="center">0.000228</td>
<td valign="top" align="center">0.014978</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CD274</italic>
</td>
<td valign="top" align="center">2.145338</td>
<td valign="top" align="center">0.000245</td>
<td valign="top" align="center">0.015765</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IDO1</italic>
</td>
<td valign="top" align="center">2.33213</td>
<td valign="top" align="center">0.000266</td>
<td valign="top" align="center">0.016581</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>RP11-44K6.4</italic>
</td>
<td valign="top" align="center">2.402228</td>
<td valign="top" align="center">0.000354</td>
<td valign="top" align="center">0.02041</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>ARAP2</italic>
</td>
<td valign="top" align="center">1.586738</td>
<td valign="top" align="center">0.000359</td>
<td valign="top" align="center">0.020475</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SAMD9L</italic>
</td>
<td valign="top" align="center">1.954036</td>
<td valign="top" align="center">0.000376</td>
<td valign="top" align="center">0.021379</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>FAS</italic>
</td>
<td valign="top" align="center">1.582688</td>
<td valign="top" align="center">0.000436</td>
<td valign="top" align="center">0.023752</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SLC30A1</italic>
</td>
<td valign="top" align="center">1.580979</td>
<td valign="top" align="center">0.000724</td>
<td valign="top" align="center">0.034599</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>GBP1</italic>
</td>
<td valign="top" align="center">2.058111</td>
<td valign="top" align="center">0.000885</td>
<td valign="top" align="center">0.039979</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_6">
<title>GO, KEGG and SPIA enrichment analysis for DEGs downstream of <italic>IFIT2</italic>
</title>
<p>Gene Ontology (GO) enrichment analysis for biological processes highlighted enrichment in GO terms, including response to virus, defense response to virus, regulation of innate immune response, and cytokine-mediated signaling pathways. Molecular function analysis indicated enrichment in functions, such as double-stranded RNA binding, nucleotidyltransferase activity, GTP binding, and cytokine receptor binding. Notably, no GO terms were enriched for cellular components (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). A table showing GO terms with associated gene lists and statistical values can be found in <xref ref-type="table" rid="T2">
<bold>Tables&#xa0;2</bold>
</xref>, <xref ref-type="table" rid="T3">
<bold>3</bold>
</xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>GO analysis showing only the top 20 significantly enriched pathways in <italic>IFIT2</italic> induced THP-1 cells with R179<italic>M. tb</italic>. <bold>(A)</bold> GO enriched terms for BP for IFIT2. <bold>(B)</bold> GO enriched terms for MF for IFIT2. The color of the bars indicates significance (adjusted P-value), and the size corresponds to the count of genes.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g005.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Top 15 enrichment GO terms for Biological Process (BP) in THP-1 cells infected with R179M.tb after IFIT2 induction with their corresponding DEGs involved.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">GOBP ID</th>
<th valign="top" align="left">Description</th>
<th valign="top" align="left">P. adjusted Value</th>
<th valign="top" align="left">Gene ID</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0009615</td>
<td valign="top" align="left">response to virus</td>
<td valign="top" align="left">2.6014E-27</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/IRF1/PLSCR1/RSAD2/OAS1/IFIH1/CXCL10/IFNB1/DTX3L/MX1/PARP9/MX2/TRIM22/CCL8/BATF3/IFI16/ISG15/ISG20/IFI44/OAS2/IFI44L/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0051607</td>
<td valign="top" align="left">defense response to virus</td>
<td valign="top" align="left">3.6276E-26</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/IRF1/PLSCR1/RSAD2/OAS1/IFIH1/CXCL10/IFNB1/DTX3L/MX1/PARP9/MX2/TRIM22/IFI16/ISG15/ISG20/OAS2/IFI44L/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0140546</td>
<td valign="top" align="left">defense response to symbiont</td>
<td valign="top" align="left">3.6276E-26</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/IRF1/PLSCR1/RSAD2/OAS1/IFIH1/CXCL10/IFNB1/DTX3L/MX1/PARP9/MX2/TRIM22/IFI16/ISG15/ISG20/OAS2/IFI44L/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0045071</td>
<td valign="top" align="left">negative regulation of viral genome replication</td>
<td valign="top" align="left">1.014E-16</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0045069</td>
<td valign="top" align="left">regulation of viral genome replication</td>
<td valign="top" align="left">2.2522E-14</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0048525</td>
<td valign="top" align="left">negative regulation of viral process</td>
<td valign="top" align="left">3.3516E-14</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0019079</td>
<td valign="top" align="left">viral genome replication</td>
<td valign="top" align="left">6.4748E-14</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/CCL8/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:1903900</td>
<td valign="top" align="left">regulation of viral life cycle</td>
<td valign="top" align="left">2.2472E-13</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/TRIM22/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0002831</td>
<td valign="top" align="left">regulation of response to biotic stimulus</td>
<td valign="top" align="left">8.4823E-13</td>
<td valign="top" align="left">
<italic>HERC5/OASL/PELI1/USP18/RIGI/IRF1/PLSCR1/RSAD2/OAS1/IFIH1/PARP14/IFNB1/DTX3L/GBP5/PARP9/IFI16/ISG15/CD274</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0050792</td>
<td valign="top" align="left">regulation of viral process</td>
<td valign="top" align="left">1.1955E-12</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/TRIM22/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0045088</td>
<td valign="top" align="left">regulation of innate immune response</td>
<td valign="top" align="left">1.0132E-10</td>
<td valign="top" align="left">
<italic>OASL/PELI1/USP18/RIGI/IRF1/PLSCR1/RSAD2/OAS1/IFIH1/PARP14/IFNB1/GBP5/PARP9/IFI16/ISG15</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0019058</td>
<td valign="top" align="left">viral life cycle</td>
<td valign="top" align="left">2.6963E-10</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/TRIM22/CCL8/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0016032</td>
<td valign="top" align="left">viral process</td>
<td valign="top" align="left">7.272E-10</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/PLSCR1/RSAD2/OAS1/IFIH1/IFNB1/MX1/PARP9/TRIM22/CCL8/IFI16/ISG15/ISG20/OAS2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0019221</td>
<td valign="top" align="left">cytokine-mediated signaling pathway</td>
<td valign="top" align="left">3.3289E-09</td>
<td valign="top" align="left">
<italic>OASL/USP18/IRF1/OAS1/CXCL10/PARP14/IFNB1/MX1/PARP9/CCL8/CXCL11/ISG15/TNFSF13B/OAS2/FAS</italic>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>All GO terms for Molecular Function (GOMF) in THP-1 cells infected with R179<italic>M.tb</italic> after IFIT2 induction with their corresponding DEGs involved.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">GOMF ID</th>
<th valign="top" align="center">Description</th>
<th valign="top" align="center">P. Adjusted Value</th>
<th valign="top" align="center">Gene ID</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0003725</td>
<td valign="top" align="left">double-stranded RNA binding</td>
<td valign="top" align="left">0.003781</td>
<td valign="top" align="left">
<italic>OASL/RIGI/OAS1/IFIH1/EIF2AK2/OAS2/SLC3A2/DHX58</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0016779</td>
<td valign="top" align="left">nucleotidyltransferase activity</td>
<td valign="top" align="left">0.013512</td>
<td valign="top" align="left">
<italic>OAS1/PARP14/PARP9/PARP12/CGAS/OAS2/MB21D2/DKC1/PNPT1/POLR1F</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0005525</td>
<td valign="top" align="left">GTP binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>RIGI/RHOU/RND3/MX1/GBP5/MX2/CGAS/GBP4/GTPBP1/TUBA1C/IFI44L/FKBP4/EHD1/RAB29/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0005126</td>
<td valign="top" align="left">cytokine receptor binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>CXCL10/IFNB1/CCL8/CXCL11/TNFSF13B/CXCL1/TNFSF10/STAT1/SMAD7/MYD88/TNF/IL1A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0005125</td>
<td valign="top" align="left">cytokine activity</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>CXCL10/IFNB1/CCL8/CXCL11/TNFSF13B/CXCL1/TNFSF10/TNF/SECTM1/BMP2/IL1A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0032813</td>
<td valign="top" align="left">tumor necrosis factor receptor superfamily <break/>binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>TNFSF13B/TNFSF10/STAT1/MYD88/TNF</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0019001</td>
<td valign="top" align="left">guanyl nucleotide binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>RIGI/RHOU/RND3/MX1/GBP5/MX2/CGAS/GBP4/GTPBP1/TUBA1C/IFI44L/FKBP4/EHD1/RAB29/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0032561</td>
<td valign="top" align="left">guanyl ribonucleotide binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>RIGI/RHOU/RND3/MX1/GBP5/MX2/CGAS/GBP4/GTPBP1/TUBA1C/IFI44L/FKBP4/EHD1/RAB29/GBP1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0003712</td>
<td valign="top" align="left">transcription coregulator activity</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>HELZ2/PARP14/PARP9/TRIB3/TRIM22/TRIM25/TFAP2A/CBX4/NUPR1/TRIM5/TBL1XR1/TRIM21/HMGA2/JMY/AKIRIN2/PTPN14/IRF4</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0005164</td>
<td valign="top" align="left">tumor necrosis factor receptor binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>TNFSF13B/TNFSF10/STAT1/TNF</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0046332</td>
<td valign="top" align="left">SMAD binding</td>
<td valign="top" align="left">0.039507</td>
<td valign="top" align="left">
<italic>RGCC/HMGA2/PML/SMAD7/DAB2/BMP2</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0019787</td>
<td valign="top" align="left">ubiquitin-like protein transferase activity</td>
<td valign="top" align="left">0.048224</td>
<td valign="top" align="left">
<italic>HERC5/PELI1/TRIM26/DTX3L/TRIM22/TRIM25/CBX4/TRIM5/MALT1/RNF13/UBE2C/TRIM21/HERC6/RNF149/PML/UBE2L6</italic>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Additionally, Gene Set Enrichment Analysis (GSEA) using the KEGG database revealed enrichment in pathways related to viral infections, including influenza A, Hepatitis C, measles, and COVID-19, as well as pathways involved in host response to various pathogens, such as NOD-like receptor signaling and cytokine-cytokine receptor signaling pathways. The overlap of genes in these pathways was depicted using an Upsetplot, illustrating the shared genes among certain pathways (<xref ref-type="supplementary-material" rid="SF4">
<bold>Supplementary Figure&#xa0;4</bold>
</xref>). A table showing specific KEGG pathways with associated gene lists, statistical values and enrichment score can be found in <xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>All Enriched KEGG Pathways in DEGs in THP-1 cells infected with R179<italic>M.tb</italic> after <italic>IFIT2</italic> induction with their corresponding enrichment scores.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">KEGG ID</th>
<th valign="top" align="left">Description</th>
<th valign="top" align="left">Enrichment Score</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">hsa05164</td>
<td valign="top" align="left">Influenza A</td>
<td valign="top" align="left">0.877667241</td>
</tr>
<tr>
<td valign="top" align="left">hsa05160</td>
<td valign="top" align="left">Hepatitis C</td>
<td valign="top" align="left">0.882222883</td>
</tr>
<tr>
<td valign="top" align="left">hsa05162</td>
<td valign="top" align="left">Measles</td>
<td valign="top" align="left">0.870922213</td>
</tr>
<tr>
<td valign="top" align="left">hsa05171</td>
<td valign="top" align="left">Coronavirus disease - COVID-19</td>
<td valign="top" align="left">0.836494333</td>
</tr>
<tr>
<td valign="top" align="left">hsa04061</td>
<td valign="top" align="left">Viral protein interaction with cytokine and cytokine receptor</td>
<td valign="top" align="left">0.875612928</td>
</tr>
<tr>
<td valign="top" align="left">hsa04621</td>
<td valign="top" align="left">NOD-like receptor signaling pathway</td>
<td valign="top" align="left">0.807225693</td>
</tr>
<tr>
<td valign="top" align="left">hsa04622</td>
<td valign="top" align="left">RIG-I-like receptor signaling pathway</td>
<td valign="top" align="left">0.89262838</td>
</tr>
<tr>
<td valign="top" align="left">hsa04060</td>
<td valign="top" align="left">Cytokine-cytokine receptor interaction</td>
<td valign="top" align="left">0.777227106</td>
</tr>
<tr>
<td valign="top" align="left">hsa04620</td>
<td valign="top" align="left">Toll-like receptor signaling pathway</td>
<td valign="top" align="left">0.855092635</td>
</tr>
<tr>
<td valign="top" align="left">hsa04623</td>
<td valign="top" align="left">Cytosolic DNA-sensing pathway</td>
<td valign="top" align="left">0.859308314</td>
</tr>
<tr>
<td valign="top" align="left">hsa05169</td>
<td valign="top" align="left">Epstein-Barr virus infection</td>
<td valign="top" align="left">0.770110534</td>
</tr>
<tr>
<td valign="top" align="left">hsa05165</td>
<td valign="top" align="left">Human papillomavirus infection</td>
<td valign="top" align="left">0.73215752</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Signaling Pathway Impact Analysis (SPIA) further supported these findings, indicating significant enrichment and activation of pathways related to cytokine-cytokine receptor interaction and chemokine signaling. Evidence suggested inhibition of TB and activation of apoptosis pathways (<xref ref-type="supplementary-material" rid="SF5">
<bold>Supplementary Figure&#xa0;5</bold>
</xref>; <xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref>).</p>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>Top 15 Pathways enriched for SPIA analysis after IFIT2 induction in THP-1 cells infected with R179<italic>M.tb</italic> and their corresponding statuses.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway ID</th>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">pPERT</th>
<th valign="top" align="left">pGFdr</th>
<th valign="top" align="left">Status</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">5164</td>
<td valign="top" align="left">Influenza A</td>
<td valign="top" align="left">0.13</td>
<td valign="top" align="left">1.15E-12</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5162</td>
<td valign="top" align="left">Measles</td>
<td valign="top" align="left">0.015</td>
<td valign="top" align="left">4.47E-09</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5168</td>
<td valign="top" align="left">Herpes simplex infection</td>
<td valign="top" align="left">0.003</td>
<td valign="top" align="left">2.26E-08</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4060</td>
<td valign="top" align="left">Cytokine-cytokine receptor interaction</td>
<td valign="top" align="left">0.004</td>
<td valign="top" align="left">5.95E-07</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5160</td>
<td valign="top" align="left">Hepatitis C</td>
<td valign="top" align="left">0.247</td>
<td valign="top" align="left">2.93E-06</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4622</td>
<td valign="top" align="left">RIG-I-like receptor signaling pathway</td>
<td valign="top" align="left">0.139</td>
<td valign="top" align="left">4.44E-06</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4620</td>
<td valign="top" align="left">Toll-like receptor signaling pathway</td>
<td valign="top" align="left">0.039</td>
<td valign="top" align="left">0.000137899</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5152</td>
<td valign="top" align="left">Tuberculosis</td>
<td valign="top" align="left">0.736</td>
<td valign="top" align="left">0.002367588</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4978</td>
<td valign="top" align="left">Mineral absorption</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.002374233</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4062</td>
<td valign="top" align="left">Chemokine signaling pathway</td>
<td valign="top" align="left">0.043</td>
<td valign="top" align="left">0.005882018</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4064</td>
<td valign="top" align="left">NF-kappa B signaling pathway</td>
<td valign="top" align="left">0.125</td>
<td valign="top" align="left">0.005882018</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5202</td>
<td valign="top" align="left">Transcriptional misregulation in cancer</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.00704798</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4623</td>
<td valign="top" align="left">Cytosolic DNA-sensing pathway</td>
<td valign="top" align="left">0.02</td>
<td valign="top" align="left">0.00704798</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4210</td>
<td valign="top" align="left">Apoptosis</td>
<td valign="top" align="left">0.033</td>
<td valign="top" align="left">0.00704798</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5143</td>
<td valign="top" align="left">African trypanosomiasis</td>
<td valign="top" align="left">0.322</td>
<td valign="top" align="left">0.009444797</td>
<td valign="top" align="left">Inhibited</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_7">
<title>Empty vector: an inducer of non-specific immune response against <italic>M. tb</italic>
</title>
<p>As seen from the preliminary experiment, the empty vector control revealed unexpected observations and outcome by showing an appreciable increase in IFIT2 gene expression and revealing antimycobacterial effects. We therefore hypothesized that the empty vector elicits a strong non-specific host-immune response in TB infection. As a result, we carried out a transcriptomic investigation to understand this outcome and tested out this hypothesis. It can be seen from <xref ref-type="table" rid="T6">
<bold>Table&#xa0;6</bold>
</xref> that 23 DEGs were identified with 4 being downregulated and 19 upregulated after extracting genes with absolute log<sub>2</sub>(fold change) &gt; 1.5. The top 30 significant genes with FDR &lt;0.05 affected by empty is represented in a volcano plot (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>).</p>
<table-wrap id="T6" position="float">
<label>Table&#xa0;6</label>
<caption>
<p>All significantly expressed genes with p. adjusted value &lt; 0.05 &amp; |log<sub>2</sub>(fold change)| &gt; 1.5 in empty vector-transfected <italic>M. tb</italic>-infected macrophages compared to control (macrophage-infected cells only).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="center">Gene</th>
<th valign="top" align="center">log<sub>2</sub>(fold change)</th>
<th valign="top" align="center">P value</th>
<th valign="top" align="center">P adjusted Value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="center">
<italic>IFIT2</italic>
</td>
<td valign="top" align="center">5.068234</td>
<td valign="top" align="center">3.17E-19</td>
<td valign="top" align="center">3.97E-15</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>HIVEP3</italic>
</td>
<td valign="top" align="center">-1.95131</td>
<td valign="top" align="center">4.95E-14</td>
<td valign="top" align="center">3.10E-10</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFIT1</italic>
</td>
<td valign="top" align="center">4.566209</td>
<td valign="top" align="center">6.47E-10</td>
<td valign="top" align="center">2.03E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1E</italic>
</td>
<td valign="top" align="center">5.270721</td>
<td valign="top" align="center">1.53E-09</td>
<td valign="top" align="center">3.19E-06</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1F</italic>
</td>
<td valign="top" align="center">4.624068</td>
<td valign="top" align="center">1.71E-08</td>
<td valign="top" align="center">2.38E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>IFIT3</italic>
</td>
<td valign="top" align="center">3.159116</td>
<td valign="top" align="center">3.43E-08</td>
<td valign="top" align="center">3.40E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT2A</italic>
</td>
<td valign="top" align="center">3.897841</td>
<td valign="top" align="center">6.35E-08</td>
<td valign="top" align="center">4.68E-05</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>HERC5</italic>
</td>
<td valign="top" align="center">3.679789</td>
<td valign="top" align="center">2.13E-07</td>
<td valign="top" align="center">0.000148</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>OASL</italic>
</td>
<td valign="top" align="center">4.037971</td>
<td valign="top" align="center">3.34E-07</td>
<td valign="top" align="center">0.000199</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CXCL1</italic>
</td>
<td valign="top" align="center">-2.70168</td>
<td valign="top" align="center">3.84E-07</td>
<td valign="top" align="center">0.000219</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT2P1</italic>
</td>
<td valign="top" align="center">3.396589</td>
<td valign="top" align="center">7.79E-07</td>
<td valign="top" align="center">0.000375</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>RTP4</italic>
</td>
<td valign="top" align="center">2.2891</td>
<td valign="top" align="center">1.07E-06</td>
<td valign="top" align="center">0.00048</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>TRIB3</italic>
</td>
<td valign="top" align="center">1.753461</td>
<td valign="top" align="center">1.96E-06</td>
<td valign="top" align="center">0.000765</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>SDS</italic>
</td>
<td valign="top" align="center">1.96803</td>
<td valign="top" align="center">2.65E-06</td>
<td valign="top" align="center">0.001005</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>PROC</italic>
</td>
<td valign="top" align="center">2.24197</td>
<td valign="top" align="center">3.93E-06</td>
<td valign="top" align="center">0.00125</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>CMPK2</italic>
</td>
<td valign="top" align="center">2.977134</td>
<td valign="top" align="center">4.73E-06</td>
<td valign="top" align="center">0.001378</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>MT1XP1</italic>
</td>
<td valign="top" align="center">3.749513</td>
<td valign="top" align="center">4.87E-06</td>
<td valign="top" align="center">0.001386</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>LZTS1</italic>
</td>
<td valign="top" align="center">-2.51467</td>
<td valign="top" align="center">6.31E-06</td>
<td valign="top" align="center">0.001718</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>DDX58</italic>
</td>
<td valign="top" align="center">2.437334</td>
<td valign="top" align="center">6.63E-06</td>
<td valign="top" align="center">0.001766</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>BATF3</italic>
</td>
<td valign="top" align="center">1.5738</td>
<td valign="top" align="center">0.000391</td>
<td valign="top" align="center">0.03548</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>KCNK5</italic>
</td>
<td valign="top" align="center">-1.82565</td>
<td valign="top" align="center">0.000453</td>
<td valign="top" align="center">0.0394</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>LURAP1L</italic>
</td>
<td valign="top" align="center">1.643754</td>
<td valign="top" align="center">0.00048</td>
<td valign="top" align="center">0.040877</td>
</tr>
<tr>
<td valign="top" align="center">
<italic>OAS1</italic>
</td>
<td valign="top" align="center">1.576962</td>
<td valign="top" align="center">0.00049</td>
<td valign="top" align="center">0.040918</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_8">
<title>GO, KEGG and SPIA enrichment analysis for DEGs downstream empty vector</title>
<p>Predictably, the GO terms were primarily enriched in response to virus, defense response to virus, defense response to symbiont, cellular response to zinc ion, cellular response to copper ion, antiviral innate immune response, response to copper ion, response to zinc ion, negative regulation of viral genome replication, regulation of viral genome replication, negative regulation of viral process, cytosolic pattern recognition receptor signaling pathway, cellular response to exogenous dsRNA, regulation of nuclease activity (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>). A table showing the top 15 GO terms and all KEGG with associated gene lists and statistical values can be found in <xref ref-type="table" rid="T7">
<bold>Tables&#xa0;7</bold>
</xref>, <xref ref-type="table" rid="T8">
<bold>8</bold>
</xref>.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>GO analysis showing only the top 20 significantly enriched pathways in Empty-vector only transfected THP-1 infected cells with R179<italic>M. tb</italic>. <bold>(A)</bold> GO enriched terms for BP <bold>(B)</bold> GO enriched terms for MF. The color of the bars indicates significance (adjusted P-value), and the size corresponds to the count of genes.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g006.tif"/>
</fig>
<table-wrap id="T7" position="float">
<label>Table&#xa0;7</label>
<caption>
<p>Top 15 enrichment GO terms for Biological Process (BP) in THP-1 cells infected with R179<italic>M.tb</italic> after transfection with empty vector only with their corresponding DEGs involved.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">GOBP ID</th>
<th valign="top" align="left">Description</th>
<th valign="top" align="left">P. Adjusted Value</th>
<th valign="top" align="left">Gene ID</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">GO:0009615</td>
<td valign="top" align="left">response to virus</td>
<td valign="top" align="left">1.12E-07</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/BATF3/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0051607</td>
<td valign="top" align="left">defense response to virus</td>
<td valign="top" align="left">1.30E-07</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0140546</td>
<td valign="top" align="left">defense response to symbiont</td>
<td valign="top" align="left">1.30E-07</td>
<td valign="top" align="left">
<italic>IFIT2/IFIT1/IFIT3/HERC5/OASL/RTP4/RIGI/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0071294</td>
<td valign="top" align="left">cellular response to zinc ion</td>
<td valign="top" align="left">0.000132</td>
<td valign="top" align="left">
<italic>MT1E/MT1F/MT2A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0071280</td>
<td valign="top" align="left">cellular response to copper ion</td>
<td valign="top" align="left">0.000234</td>
<td valign="top" align="left">
<italic>MT1E/MT1F/MT2A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0140374</td>
<td valign="top" align="left">antiviral innate immune response</td>
<td valign="top" align="left">0.000234</td>
<td valign="top" align="left">
<italic>IFIT1/RIGI/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0046688</td>
<td valign="top" align="left">response to copper ion</td>
<td valign="top" align="left">0.000813</td>
<td valign="top" align="left">
<italic>MT1E/MT1F/MT2A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0010043</td>
<td valign="top" align="left">response to zinc ion</td>
<td valign="top" align="left">0.001077</td>
<td valign="top" align="left">
<italic>MT1E/MT1F/MT2A</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0045071</td>
<td valign="top" align="left">negative regulation of viral genome replication</td>
<td valign="top" align="left">0.00154</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0045069</td>
<td valign="top" align="left">regulation of viral genome replication</td>
<td valign="top" align="left">0.0051</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0048525</td>
<td valign="top" align="left">negative regulation of viral process</td>
<td valign="top" align="left">0.005291</td>
<td valign="top" align="left">
<italic>IFIT1/OASL/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0002753</td>
<td valign="top" align="left">cytosolic pattern recognition receptor signaling pathway</td>
<td valign="top" align="left">0.005291</td>
<td valign="top" align="left">
<italic>OASL/RIGI/OAS1</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0071360</td>
<td valign="top" align="left">cellular response to exogenous dsRNA</td>
<td valign="top" align="left">0.005291</td>
<td valign="top" align="left">
<italic>IFIT1/RIGI</italic>
</td>
</tr>
<tr>
<td valign="top" align="left">GO:0032069</td>
<td valign="top" align="left">regulation of nuclease activity</td>
<td valign="top" align="left">0.00776</td>
<td valign="top" align="left">
<italic>OASL/OAS1</italic>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T8" position="float">
<label>Table&#xa0;8</label>
<caption>
<p>All KEGG enriched pathways in THP-1 cells infected with R179<italic>M.tb</italic> after empty vector only transfection with their corresponding enrichment score.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">KEGG ID</th>
<th valign="top" align="left">Description</th>
<th valign="top" align="left">Enrichment Score</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">hsa04978</td>
<td valign="top" align="left">Mineral absorption</td>
<td valign="top" align="left">0.904178</td>
</tr>
<tr>
<td valign="top" align="left">hsa04742</td>
<td valign="top" align="left">Taste transduction</td>
<td valign="top" align="left">-0.79694</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The SPIA results for the empty vector, as shown in <xref ref-type="table" rid="T9">
<bold>Table&#xa0;9</bold>
</xref>, <xref ref-type="supplementary-material" rid="SF6">
<bold>Supplementary Figure&#xa0;6</bold>
</xref>, revealed intriguing findings that underscore the distinct effectiveness of IFIT2 induction in anti-mycobacterial activity compared to the empty vector. Notably, the analysis demonstrated that pathways such as the cytokine-cytokine mediated interaction pathway, chemokine signaling pathway, and apoptosis were inhibited by the empty vector but were activated downstream by IFIT2 induction.</p>
<table-wrap id="T9" position="float">
<label>Table&#xa0;9</label>
<caption>
<p>Top 15 Pathways enriched for SPIA analysis after empty vector transfection in THP-1 cells infected with R179<italic>M.tb</italic> and their corresponding status.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Pathway ID</th>
<th valign="top" align="left">Pathway</th>
<th valign="top" align="left">pPERT</th>
<th valign="top" align="left">pGFdr</th>
<th valign="top" align="left">Status</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">4060</td>
<td valign="top" align="left">Cytokine-cytokine receptor interaction</td>
<td valign="top" align="left">0.014</td>
<td valign="top" align="left">5.90E-05</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">5164</td>
<td valign="top" align="left">Influenza A</td>
<td valign="top" align="left">0.075</td>
<td valign="top" align="left">0.001041403</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4623</td>
<td valign="top" align="left">Cytosolic DNA-sensing pathway</td>
<td valign="top" align="left">0.03</td>
<td valign="top" align="left">0.008402814</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5168</td>
<td valign="top" align="left">Herpes simplex infection</td>
<td valign="top" align="left">0.046</td>
<td valign="top" align="left">0.015206414</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5323</td>
<td valign="top" align="left">Rheumatoid arthritis</td>
<td valign="top" align="left">0.271</td>
<td valign="top" align="left">0.016358433</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5162</td>
<td valign="top" align="left">Measles</td>
<td valign="top" align="left">0.073</td>
<td valign="top" align="left">0.023851615</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5160</td>
<td valign="top" align="left">Hepatitis C</td>
<td valign="top" align="left">0.58</td>
<td valign="top" align="left">0.024252426</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4622</td>
<td valign="top" align="left">RIG-I-like receptor signaling pathway</td>
<td valign="top" align="left">0.146</td>
<td valign="top" align="left">0.024655959</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4978</td>
<td valign="top" align="left">Mineral absorption</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0.034865963</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4064</td>
<td valign="top" align="left">NF-kappa B signaling pathway</td>
<td valign="top" align="left">0.153</td>
<td valign="top" align="left">0.037906359</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">5120</td>
<td valign="top" align="left">Epithelial cell signaling in Helicobacter pylori infection</td>
<td valign="top" align="left">0.445</td>
<td valign="top" align="left">0.037906359</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4010</td>
<td valign="top" align="left">MAPK signaling pathway</td>
<td valign="top" align="left">0.75</td>
<td valign="top" align="left">0.096624766</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">5132</td>
<td valign="top" align="left">Salmonella infection</td>
<td valign="top" align="left">0.699</td>
<td valign="top" align="left">0.099246083</td>
<td valign="top" align="left">Inhibited</td>
</tr>
<tr>
<td valign="top" align="left">4150</td>
<td valign="top" align="left">mTOR signaling pathway</td>
<td valign="top" align="left">0.344</td>
<td valign="top" align="left">0.147441236</td>
<td valign="top" align="left">Activated</td>
</tr>
<tr>
<td valign="top" align="left">4062</td>
<td valign="top" align="left">Chemokine signaling pathway</td>
<td valign="top" align="left">0.026</td>
<td valign="top" align="left">0.148894006</td>
<td valign="top" align="left">Inhibited</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_9">
<title>Comparing the transcriptomic profiles of <italic>IFIT2</italic>, empty vector and <italic>CKB</italic>
</title>
<p>In comparison to <italic>IFIT2</italic>, the treatment with empty vector and <italic>CKB</italic> which served as controls for the present study revealed unexpected results in their transcriptomic profiles. To identify the commonalities and potential specific genes to each treatment, Venny online software v 2.1 (<ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link>) was used to obtain the intersection of <italic>IFIT2</italic>/empty vector, <italic>IFIT2</italic>/<italic>CKB</italic>, and <italic>IFIT2</italic>/empty vector/<italic>CKB</italic>. Venn diagrams showing number and percentage of overlapping genes and genes exclusive to <italic>IFIT2 M. tb</italic> infected THP-1 cells can be found in <xref ref-type="supplementary-material" rid="SF7">
<bold>Supplementary Figure&#xa0;7</bold>
</xref>. For <italic>IFIT2</italic>/empty vector comparison, the result showed that 20 genes were common to both, 50 genes were exclusive to <italic>IFIT2</italic> and 3 genes exclusive to Empty Vector (<xref ref-type="supplementary-material" rid="SF7">
<bold>Supplementary Figure&#xa0;7A</bold>
</xref>)<italic>. IFIT2</italic>/<italic>CKB</italic> comparison results also revealed that 50 genes overlapped, 20 genes were <italic>IFIT2</italic> specific genes and 5 were specific to <italic>CKB</italic> (<xref ref-type="supplementary-material" rid="SF7">
<bold>Supplementary Figure&#xa0;7B</bold>
</xref>). Lastly, for the three comparisons, the results showed that there were 20 DEGs common to all the three groups, 20 specific genes in <italic>IFIT2</italic>, 3 specific genes in Empty Vector and 3 specific genes for <italic>CKB</italic> (<xref ref-type="supplementary-material" rid="SF7">
<bold>Supplementary Figure&#xa0;7C</bold>
</xref>).</p>
</sec>
<sec id="s3_10">
<title>Protein-protein interaction networks</title>
<p>A protein-protein interaction (PPI) network was constructed using the STRING database to assess functional associations among the proteins encoded by the DEGs of IFIT2 induction in <italic>M. tb</italic>-infected THP-1 cells. Each node represented a DEG, while connections between nodes indicated established interactions (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). This analysis provided insight into the functional relationships among the DEGs, enhancing our understanding of their roles in TB infection. Within the PPI network, several hub genes were identified based on their high degree of connectivity. Key hub genes include ISG15, RSAD2, IFIT3, IFI44L, suggesting their central roles in mediating interactions among DEGs induced by <italic>M. tb</italic> infection.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Protein-Protein Interactions of DEGs with p-adjusted values &lt;0.05 and absolute log<sub>2</sub>(fold change) &gt;1.5 for <italic>IFIT2</italic>. This is a STRING-generated physical subnetwork (the edges indicate that the proteins are part of a physical complex). Nodes are colored based on the clustering using the Markov Cluster Algorithm (MCL) option of STRING version 12.0.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g007.tif"/>
</fig>
</sec>
<sec id="s3_11">
<title>RT-qPCR validation of selected DEGs</title>
<p>Gene expression levels were quantified using RT-qPCR for five selected key DEGs identified downstream of IFIT2 which includes, CMPK2, RSAD2, ISG15,IFI44L and IFI44. The qPCR results were consistent with the AmpliSeq data, demonstrating robust fold changes and statistical significance (p &lt; 0.05) albeit not for ISG15 and RSAD2 (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8</bold>
</xref>). This concordance reinforces the reliability of our transcriptomic analysis and highlights the potential role of these interferon-stimulated genes (ISGs) in the antimycobacterial activity of IFIT2. The enhanced expression of these genes suggests their potential contribution to the host&#x2019;s immune defense mechanisms, offering promising targets for future therapeutic strategies against TB.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Validation of the selected genes by qPCR. IFIT2 expression was induced in THP-1 macrophages infected with <italic>M. tb</italic> or left uninfected, followed by RNA extraction. Three biological replicates were run in triplicates for each sample and analyzed by Roche Light Cycler 96 software to obtain the relative expression in relation to the reference genes UBC and GAPDH. One-way ANOVA with Tukey&#x2019;s post-test was used to determine significance. *p-value &lt; 0.05, **p-value &lt;0.01, ***p-value &lt;0.001, ****p-value &lt;0.0001. GAPDH (Glyceraldehyde-3-phospate dehydrogenase), UBC (Ubiquitin C), IFIT2 (Interferon induced protein with tetratricopeptide repeat 2), ISG15 (interferon stimulated 15), IFI44L (Interferon-Induced Protein 44-Like), RSAD2 (Radical S-adenosyl methionine domain containing 2), CMPK2 (Cytidine/uridine monophosphate kinase 2), IFI44 (Interferon-Induced Protein 44).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-15-1536446-g008.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>With the rise of drug-resistant TB, there is a growing interest in targeting host genes for improved therapy due to the less likelihood of host resistance developing. Recent studies have highlighted the potential role of the IFIT protein family in mycobacterial killing. Among them, IFIT2 stands out for its unique ability to inhibit cancer cell proliferation, making it a promising candidate for further research against <italic>M. tb</italic>. In this study, we explored the transcriptomic profile of the human IFIT2 gene induced in macrophages infected with <italic>M. tb</italic>, to elucidate its underlying anti-mycobacterial mechanisms.</p>
<p>Preliminary experiments to determine the best IFIT2 vector construct for our high-throughput experiments investigated the impact of the FLAG tag position (N-terminus or C-terminus) on IFIT2&#x2019;s expression and anti-mycobacterial activity. Our findings revealed that the C-Flagged IFIT2 vector construct recorded high CFU counts and low IFIT2 gene expression levels. This is consistent with previous studies that observed placing a tag at the C-terminus can compromise protein stability and function. Studies on other proteins, such as the molybdoenzyme YedY (<xref ref-type="bibr" rid="B41">Sabaty et&#xa0;al., 2013</xref>) and antiviral gene viperin (<xref ref-type="bibr" rid="B20">Jiang et&#xa0;al., 2008</xref>), have shown similar detrimental effects of C-terminal tagging on enzymatic activity and antiviral function, respectively. Conversely, both the N-Flagged and No-Flag IFIT2 vector constructs showed high gene expression and significant anti-mycobacterial activity, indicating that the N-terminal tag or its absence did not hinder IFIT2&#x2019;s functionality. These results support the preference for N-terminal tags in literature highlighting their advantages over C-terminal tags, which includes efficient translation efficiency and ease of tag removal from the target protein enhancing protein stability (<xref ref-type="bibr" rid="B33">Malhotra, 2009</xref>). Studies with other proteins, like recombinant antibody fragments in <italic>E. coli</italic> using antibody M1 (<xref ref-type="bibr" rid="B39">Pl&#xfc;ckthun, 1992</xref>) and Cytochrome P450 119 (CYP119) (<xref ref-type="bibr" rid="B4">Aslantas and Surmeli, 2019</xref>), have demonstrated improved expression levels and stability when tagged at the N-terminus compared to the C-terminus. Our present study reinforces that N-terminal tagging is advantageous over C-terminal tagging for maintaining protein integrity and function.</p>
<p>Our transcriptomic and bioinformatic analyses identified a comprehensive set of differentially expressed genes (DEGs) and associated pathways, revealing the complex interactions between host genes and mycobacterial infection. Notably, many of the significant DEGs participate in type I interferon (IFN) signaling, which is crucial for antiviral defense and immune response. Previous studies have established that type I IFNs are typically activated by mycobacterial infection (<xref ref-type="bibr" rid="B1">Akter et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B29">Madden et&#xa0;al., 2023</xref>). Downstream of IFIT2 induction, we found several interferon-stimulated genes (ISGs) such as IFIT1, IFIT3, OASL, OAS1, ISG15, IFI44L, MX1, MX2, RSAD2, CMPK2, and HERC5 upregulated. <xref ref-type="bibr" rid="B31">Madhvi et&#xa0;al. (2020)</xref> reported similar upregulation of these genes post <italic>M. tb</italic> infection in <italic>M. tb</italic>-infected hMDMs (<xref ref-type="bibr" rid="B31">Madhvi et&#xa0;al., 2020</xref>), however it is important to note that our study revealed higher log<sub>2</sub>(fold change) in IFIT2-induced R179 <italic>M. tb</italic>-infected THP-1 cells compared to R179 <italic>M. tb</italic>-infected hMDMs without IFIT2 induction. This suggests a direct association between IFIT2&#x2019;s induction and the observed higher gene expressions of these ISGs. The higher fold changes in these ISGs likely contributed to IFIT2&#x2019;s anti-mycobacterial effects, though this warrants further investigation. Interestingly, all these genes were found upregulated downstream of <italic>IFIT2</italic> in uninfected macrophages (with <italic>IFIT2</italic> induction) confirming that the induction of <italic>IFIT2</italic> leading to the upregulation of these genes could be independent of <italic>M. tb</italic> infection.</p>
<p>Additionally, several downstream genes identified in this study have documented roles in restricting mycobacterial growth. For example, the knock-up of interferon-induced protein 44-like (IFI44L) reduced mycobacterial growth after 24 hours, while its knock-down increased growth. <xref ref-type="bibr" rid="B21">Jiang et&#xa0;al. (2021)</xref> suggested that IFI44L promotes macrophage polarization and inflammatory cytokine secretion, inhibiting <italic>M. tb</italic> infection. Its upregulation was observed after rifampicin treatment, further restricting <italic>M. tb</italic> survival (<xref ref-type="bibr" rid="B21">Jiang et&#xa0;al., 2021</xref>). However, its homologous gene, IFI44, does not have a known role in TB infection but is shown to play a significant role in tumor cell recognition and immune response modulation. Furthermore, the silencing of oligoadenylate synthetase genes (OAS1, OAS2, OAS3) and oligoadenylate synthetase-like (OASL) was linked to increased mycobacterial growth, highlighting their potential roles in host defense (<xref ref-type="bibr" rid="B27">Leisching et&#xa0;al., 2017</xref>, <xref ref-type="bibr" rid="B24">2019</xref>). Silencing the OASs significantly increases <italic>M. tb</italic> growth in THP-1 cells at 96 hours post-infection (<xref ref-type="bibr" rid="B24">Leisching et&#xa0;al., 2019</xref>). Previous transcriptomic studies revealed that these OASs distinguish latent TB from active TB (<xref ref-type="bibr" rid="B6">Berry et&#xa0;al., 2010</xref>; <xref ref-type="bibr" rid="B36">Ottenhoff et&#xa0;al., 2012</xref>). OASL expression is strongly induced by <italic>M. tb</italic> after 24 hours, and its knockdown led to an increase in <italic>M. tb</italic> after 96 hours (<xref ref-type="bibr" rid="B27">Leisching et&#xa0;al., 2017</xref>). Interferon regulatory factor 1 (IRF1) expression decreased mycobacterial survival in macrophages, playing a crucial role in <italic>M. tb&#x2019;s</italic> intracellular survival, and is found to be high in TB patients compared to healthy controls (<xref ref-type="bibr" rid="B57">Zhou et&#xa0;al., 2019</xref>; <xref ref-type="bibr" rid="B51">Wu et&#xa0;al., 2021</xref>). Contrarily, Viperin (RSAD2) has been reported to increase <italic>M. tb</italic> infection in mice (<xref ref-type="bibr" rid="B58">Zhou et&#xa0;al., 2022</xref>). This may reflect a decrease in <italic>M. tb</italic> uptake rather than killing. Though the data showed a slight increase in <italic>M. tb</italic> infection with Viperin induction, the biological relevance remains uncertain. A research study found that viperin catalyzes the conversion of cytidine triphosphate to 3&#x2019;-deoxy-3&#x2019;,4&#x2019;-didehydro-cytidine triphosphate, which acts as a chain terminator for RNA polymerases in viruses (<xref ref-type="bibr" rid="B40">Rivera-Serrano et&#xa0;al., 2017</xref>). CMPK2 plays a crucial role in nucleic acid synthesis in macrophages, with its expression induced by pattern-associated molecular patterns (PAMP) like lipopolysaccharide (LPS), a component of gram-negative bacterial outer membranes (<xref ref-type="bibr" rid="B22">Kim et&#xa0;al., 2021</xref>).</p>
<p>Our study also revealed the upregulation of chemokine-related genes including CXCL10, CXCL11, TNFSF10, TNFSF13B downstream of IFIT2. Previous research indicates that mycobacterial infection induces the release of chemokines like CXCL10 and CXCL11, crucial for immune mediator formation and granuloma development in TB-specific T cells (<xref ref-type="bibr" rid="B13">Domingo-Gonzalez et&#xa0;al., 2016</xref>). CXCL10 has been proposed as a potential TB biomarker, with its serum levels decreasing post-treatment compared to non-responders. CXCL10, though its exact role in TB remains unclear, has potential as a biomarker for monitoring TB treatment response (<xref ref-type="bibr" rid="B3">Almeida et&#xa0;al., 2009</xref>). Levels of CXCL10 and CXCL11 also distinguish TB infections from healthy controls (<xref ref-type="bibr" rid="B42">Sampath et&#xa0;al., 2023</xref>). TNFSF13B (B cell activating factor) is implicated in pulmonary diseases, promoting B cell maturation and proliferation (<xref ref-type="bibr" rid="B16">Fan et&#xa0;al., 2021</xref>). TNFSF10 shows increased expression during <italic>M. tb</italic> infection, yet its specific role remains uncertain (<xref ref-type="bibr" rid="B5">Badr and H&#xe4;cker, 2019</xref>).</p>
<p>We also observed the upregulation of genes involved in ISGylation (ISG15, HERC5, USP18), a process where ISG15 is covalently attached to target proteins, enhancing host defense against intracellular pathogens. ISGylation has been shown to protect mice against <italic>M. tb</italic> (<xref ref-type="bibr" rid="B23">Kimmey et&#xa0;al., 2017</xref>), with ISG15 deficiency in humans linked to increased mycobacterial susceptibility (<xref ref-type="bibr" rid="B7">Bogunovic et&#xa0;al., 2012</xref>). A study found that HERC5-mediated ISGylation of the Phosphatase and Tensin Homolog (PTEN) activated the P13K-ART signaling pathway, causing proinflammatory cytokine production and promoting <italic>M. tb</italic> clearance (<xref ref-type="bibr" rid="B15">Du et&#xa0;al., 2023</xref>). USP18 on the other hand reverses ISGylation by detaching ISG15 from target proteins (<xref ref-type="bibr" rid="B32">Malakhov et&#xa0;al., 2002</xref>). Its expression was observed to increase during <italic>M. tb</italic> infection, and a study found that USP18 levels significantly rise in TB patients after isoniazid (INH) treatment, suggesting its potential as a marker for monitoring therapy response (<xref ref-type="bibr" rid="B11">De Oyarzabal et&#xa0;al., 2019</xref>).</p>
<p>We also identified apoptosis-related genes downstream of IFIT2 in <italic>M. tb</italic>-infected macrophages, including FAS, XAF1, TNFSF10, and TNFSF13B. Consistent with previous data, TNFSF10 and XAF1 were upregulated in T cells of active TB patients compared to healthy individuals (<xref ref-type="bibr" rid="B49">Wang et&#xa0;al., 2023</xref>). Research indicates that the FAS receptor&#x2019;s interaction with its ligand activates caspase-8 (CASP8) through the Fas-associated death domain (FADD), leading to apoptosis. Previous studies have already established the involvement of <italic>IFIT2</italic> in apoptosis and attributed this to its ability to inhibit cancer cell proliferation (<xref ref-type="bibr" rid="B35">Ohsugi et&#xa0;al., 2017</xref>). However, the direct link between IFIT2&#x2019;s apoptotic effects and anti-mycobacterial activity requires experimental validation. XAF1 promotes apoptosis through p53 (<xref ref-type="bibr" rid="B49">Wang et&#xa0;al., 2023</xref>) while MT1F, a tumor suppressor, inhibits cancer cell migration and invasion (<xref ref-type="bibr" rid="B54">Yan et&#xa0;al., 2012</xref>). Among highly expressed genes with log<sub>2</sub>(fold change) &gt; 1.5, only two genes, HIVEP3 and LZTS1, were found downregulated downstream of IFIT2. HIVEP3, a transcription factor, binds to genes involve in cell progression and differentiation (<xref ref-type="bibr" rid="B2">Allen et&#xa0;al., 2002</xref>), while LZTS1 acts as a tumor suppressor (<xref ref-type="bibr" rid="B56">Zhou et&#xa0;al., 2015</xref>). Their downregulation suggests potential impacts on immune regulation, underscoring the need for further research into their specific roles in mycobacterial infection.</p>
<p>The significant enrichment of Gene Ontology (GO) terms related to &#x201c;defense response to virus&#x201d; and &#x201c;cytokine-mediated signaling pathway&#x201d; suggests that upregulated DEGs contribute to a broad spectrum of immune responses. Functional analysis revealed involvement in crucial pathways such as cytokine-cytokine receptor interaction and Jak-STAT signaling, essential for sustaining immune responses against intracellular pathogens. KEGG pathway analysis supported these findings, indicating significant impacts on these pathways and inhibition of the tuberculosis pathway, highlighting IFIT2&#x2019;s role in enhancing immune responses to eliminate <italic>M. tb</italic>. Protein-protein interaction network analysis identified key hub genes (ISG15, RSAD2, IFI44L, IFIT3) central to the IFIT2-mediated immune response, suggesting coordinated efforts to enhance macrophage function. RT-qPCR validation of key DEGs (ISG15, CMPK2, RSAD2, IFI44L, IFI44) confirmed the reliability and credibility of our AmpliSeq data, reinforcing the biological relevance of identified genes and their roles in TB.</p>
<p>An interesting finding from this study is the observed anti-mycobacterial activity and IFIT2 gene expression in the control groups, specifically the empty vector and the non-specific gene vector (CKB). Our transcriptomic analysis revealed that the empty vector induced a non-specific antiviral response in the host cell by upregulating genes known as the metallothioneins including MT1E, MT1F, MT2A, MT2P1. These genes are involved in copper (Cu) and zinc (Zn) homeostasis, which play crucial roles in innate and adaptive immunity (<xref ref-type="bibr" rid="B48">Vignesh and Deepe, 2017</xref>). Zinc deficiency has been linked to impaired immune cell production and increased susceptibility to infections (<xref ref-type="bibr" rid="B17">Haase and Rink, 2014</xref>), while excess zinc can be cytotoxic (<xref ref-type="bibr" rid="B44">Shankar and Prasad, 2018</xref>). Though the precise roles of metallothioneins in TB immunity are not well established, they likely regulate host immunity. During TB infection, human macrophages deliver zinc into phagolysosomes to intoxicate the pathogen, contrary to the traditional belief in metal starvation as an antimicrobial defense (<xref ref-type="bibr" rid="B9">Botella et&#xa0;al., 2011</xref>). Additionally, the empty vector significantly upregulated several interferon-stimulated genes (ISGs) with known antiviral functions, including IFIT1, IFIT2, IFIT3, HERC5, OASL and RTP4. This aligns with previous findings that empty vectors can trigger cellular responses resembling viral infections (<xref ref-type="bibr" rid="B18">Hagen et&#xa0;al., 2015</xref>). These data support the hypothesis that empty vectors elicit a non-specific antiviral response, leading to observed anti-mycobacterial effects and the induced expression of the antiviral gene IFIT2.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>This study provides valuable insights into the transcriptomic profile of IFIT2-induced expression in TB, highlighting the downstream contributors and signaling pathways involved in the intracellular killing of <italic>M. tb</italic>. The findings underscore the potential of IFIT2 as a therapeutic target, paving the way for future research to exploit its immune-modulating properties for TB treatment. The upregulation of immune-related genes and inhibition of TB pathways suggest that enhancing IFIT2 expression or mimicking its effects could provide new treatment avenues. By advancing our understanding of host-pathogen interactions, this study contributes to the ongoing efforts to develop more effective TB therapies. Future research should explore the therapeutic potential of IFIT2, including the development of small molecules to modulate its activity. Broader transcriptomic and proteomic analyses, involving multiple cell types and <italic>in vivo</italic> models, are necessary to validate and extend these findings, providing a comprehensive understanding of host-pathogen interactions downstream of IFIT2. This will pave the way for innovative TB treatments leveraging host-targeted strategies to combat drug-resistant strains.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>Data generated and analyzed during this study have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE297207.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The manuscript presents research on animals that do not require ethical approval for their study.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>EM: Data curation, Formal Analysis, Investigation, Methodology, Software, Validation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. BB: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing &#x2013; review &amp; editing. RP: Data curation, Investigation, Project administration, Supervision, Validation, Writing &#x2013; review &amp; editing, Methodology.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Research Foundation of South Africa (UID 129379, 2021) and the South African Medical Research Council Centre for Tuberculosis Research (SAMRC-CTR).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors would like to thank the National Research Foundation of South Africa for funding this paper. We also acknowledge the support of the South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. The authors acknowledge the German Academic Exchange Service (DAAD) for their immense support.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2025.1536446/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcimb.2025.1536446/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.zip" id="SM1" mimetype="application/zip">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>Knock-up of <italic>IFIT2</italic> using different vector constructs (N-Flagged <italic>IFIT2</italic>, C-Fagged <italic>IFIT2</italic>, and No-Flag <italic>IFIT2</italic>) in <italic>M. bovis</italic> BCG-infected THP-1 cells assessed by CFUs and relative gene expression. No-flag 1 and No-flag 2 represent technical replicates <bold>(A)</bold> Intracellular mycobacteria via CFU counts at 24 h post-infection. <bold>(B)</bold> Relative mRNA expression levels of <italic>IFIT2</italic>. Included in the graph are the statistical significance (ANOVA and Tukey post-test) levels for the indicated vector treatments against the 24 h infected control. *p-value &lt; 0.05, **p-value &lt;0.01, ***p-value &lt;0.001, ****p-value &lt; 0.0001. TR: Transfection Reagent, ns: not significant.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF2" mimetype="application/zip">
<label>Supplementary Figure&#xa0;2</label>
<caption>
<p>Knock-up of <italic>IFIT2</italic> using different vector constructs (N-Flagged <italic>IFIT2</italic> and No-Flag <italic>IFIT2</italic>) in R179 <italic>M.tb</italic>-infected THP-1 cells assessed by CFUs and relative gene expression. No-flag 1 and No-flag 2 represent technical replicates <bold>(A)</bold> Intracellular mycobacteria via CFU counts at 24 h post-infection. <bold>(B)</bold> Relative mRNA expression levels of <italic>IFIT2</italic> in various samples. Included in the graph are the statistical significance (ANOVA and Tukey post-test) levels for the indicated vector treatments against the 24hours infected control. *p-value &lt; 0.05, **p-value &lt;0.01, ***p-value &lt;0.001. TR, Transfection Reagent; ns, not significant; CKB, creatine kinase B (non-specific vector).</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF3" mimetype="application/zip">
<label>Supplementary Figure&#xa0;3</label>
<caption>
<p>MA plot showing the log-fold change versus the mean expression for the treatment groups. <bold>(A)</bold> IFIT2-transfected THP-1 cells infected with R179M.tb, <bold>(B)</bold> Empty Vector-transfected THP-1 cells infected with R179M.tb, and <bold>(C)</bold> CKB-transfected THP-1 cells infected with R179M.tb) compared to control (R179M.tb-infected THP-1 cells only). Blue dots indicate significant differentially expressed genes (DEGs); false discover rate (FDR) &lt;0.05.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF4" mimetype="application/zip">
<label>Supplementary Figure&#xa0;4</label>
<caption>
<p>Upsetplot for Enriched KEGG pathways in DEGs (in THP-1 cells infected with R179<italic>M.tb</italic> after IFIT2 induction. Each dot represents a gene. The plot shows unique genes to specific pathways and their overlaps in different pathways.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF5" mimetype="application/zip">
<label>Supplementary Figure&#xa0;5</label>
<caption>
<p>SPIA two-way evidence plot for THP-1 cells infected with R179M.tb with the induced expression of IFIT2. SPIA of all DEGs based on pathway gene enrichment (pNDE) and pathway perturbations (pPERT) considering gene placement and topology within the pathway. Both pNDE and pPERT are used to determine global significance. Each dot represents a pathway that contains at least one DEG. The impact analysis plots each pathway based on pNDE and pPERT. Pathways above the solid blue line are significant following FDR correction (pGFDR &lt; 0.05). Pathways above the solid red line are significant following Bonferroni correction (pGFWER &lt; 0.05). The pathways associated with the pathway IDs in this figure can be found in <xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref>.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF6" mimetype="application/zip">
<label>Supplementary Figure&#xa0;6</label>
<caption>
<p>SPIA two-way evidence plot for THP-1 cells infected with R179<italic>M.tb</italic> after transfecting with empty vector. SPIA of all DEGs based on pathway gene enrichment (pNDE) and pathway perturbations (pPERT) considering gene placement and topology within the pathway. Both pNDE and pPERT are used to determine global significance. Each dot represents a pathway that contains at least one DEG. The impact analysis plots each pathway based on pNDE and pPERT. Pathways above the solid blue line are significant following FDR correction (pGFDR &lt; 0.05). Pathways above the solid red line are significant following Bonferroni correction (pGFWER &lt; 0.05). The pathways associated with the pathway IDs in this figure can be found in <xref ref-type="table" rid="T9">
<bold>Table&#xa0;9</bold>
</xref>.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="DataSheet1.zip" id="SF7" mimetype="application/zip">
<label>Supplementary Figure&#xa0;7</label>
<caption>
<p>Differential gene expression treatment comparisons by Venn diagram analysis. <bold>(A)</bold> The number of DEGs that overlap between <italic>IFIT2 M. tb</italic> infected THPS-1 cells vs <italic>M. tb</italic> Infected THP-1 cells <bold>(B)</bold> The number of DEGs that overlap between <italic>IFIT2 M. tb</italic> infected THP-1 cells vs <italic>M. tb</italic> Infected THP-1 cells <bold>(C)</bold> Number of differential gene expression patterns that overlap in all the various treatment groups.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akter</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Chauhan</surname> <given-names>K. S.</given-names>
</name>
<name>
<surname>Dunlap</surname> <given-names>M. D.</given-names>
</name>
<name>
<surname>Chore&#xf1;o-Parra</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Esaulova</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Mycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes</article-title>. <source>Cell Rep.</source> <volume>39</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2022.110983</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname> <given-names>C. E.</given-names>
</name>
<name>
<surname>Mak</surname> <given-names>C. H.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L. C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>The &#x3ba;B transcriptional enhancer motif and signal sequences of V(D)J recombination are targets for the zinc finger protein HIVEP3/KRC: A site selection amplification binding study</article-title>. <source>BMC Immunol.</source> <volume>3</volume>, <fpage>1</fpage>&#x2013;<lpage>23</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2172-3-10</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almeida</surname> <given-names>C.</given-names>
</name>
<name>
<surname>de</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Abramo</surname> <given-names>C.</given-names>
</name>
<name>
<surname>de S.</surname> <given-names>C. C.</given-names>
</name>
<name>
<surname>Mazzoccoli</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Ferreira</surname> <given-names>A. P.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Anti-mycobacterial treatment reduces high plasma levels of CXC-chemokines detected in active tuberculosis by cytometric bead array</article-title>. <source>Mem. Inst. Oswaldo Cruz</source> <volume>104</volume>, <fpage>1039</fpage>&#x2013;<lpage>1041</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1590/S0074-02762009000700018</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aslantas</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Surmeli</surname> <given-names>N. B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effects of N-terminal and C-terminal polyhistidine tag on the stability and function of the thermophilic P450 CYP119</article-title>. <source>Bioinorg. Chem. Appl.</source> <volume>2019</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/8080697</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badr</surname> <given-names>M. T.</given-names>
</name>
<name>
<surname>H&#xe4;cker</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Gene expression profiling meta-analysis reveals novel gene signatures and pathways shared between tuberculosis and rheumatoid arthritis</article-title>. <source>PLoS One</source> <volume>14</volume>, <fpage>1</fpage>&#x2013;<lpage>16</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0213470</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berry</surname> <given-names>M. P. R.</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>C. M.</given-names>
</name>
<name>
<surname>McNab</surname> <given-names>F. W.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Bloch</surname> <given-names>S. A. A.</given-names>
</name>
<name>
<surname>Oni</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title>. <source>Nature</source> <volume>466</volume>, <fpage>973</fpage>&#x2013;<lpage>977</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature09247</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogunovic</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Byun</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Durfee</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Abhyankar</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sanal</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Mansouri</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Mycobacterial disease and impaired IFN-&#x3b3; immunity in humans with inherited ISG15 deficiency</article-title>. <source>Sci. (80-.).</source> <volume>337</volume>, <fpage>1684</fpage>&#x2013;<lpage>1688</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1224026</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Booth</surname> <given-names>W. T.</given-names>
</name>
<name>
<surname>Schlachter</surname> <given-names>C. R.</given-names>
</name>
<name>
<surname>Pote</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ussin</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Mank</surname> <given-names>N. J.</given-names>
</name>
<name>
<surname>Klapper</surname> <given-names>V.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Impact of an N&#x2212;terminal polyhistidine tag on protein thermal stability</article-title>. <source>ACS Omega</source> <volume>3</volume>, <fpage>760</fpage>&#x2013;<lpage>768</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acsomega.7b01598</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botella</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Peyron</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Levillain</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Poincloux</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Poquet</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Brandli</surname> <given-names>I.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Mycobacterial P 1-Type ATPases mediate resistance to Zinc poisoning in human macrophages</article-title>. <source>Cell Host Microbe</source> <volume>10</volume>, <fpage>248</fpage>&#x2013;<lpage>259</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chom.2011.08.006</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bustin</surname> <given-names>S. A.</given-names>
</name>
<name>
<surname>Benes</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Garson</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Hellemans</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Huggett</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Kubista</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments</article-title>. <source>Clin. Chem.</source> <volume>55</volume>, <fpage>611</fpage>&#x2013;<lpage>622</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1373/clinchem.2008.112797</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Oyarzabal</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Garc&#xed;a</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Rangel-Escare&#xf1;o</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Ferreyra-Reyes</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Orozco</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Herrera</surname> <given-names>M. T.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Expression of USP18 and IL2RA is increased in individuals receiving latent tuberculosis treatment with isoniazid</article-title>. <source>J. Immunol. Res.</source> <volume>2019</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/1297131</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname> <given-names>M. S.</given-names>
</name>
<name>
<surname>Farzan</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>The broad-spectrum antiviral functions of IFIT and IFITM proteins</article-title>. <source>Nat. Rev. Immunol.</source> <volume>13</volume>, <fpage>46</fpage>&#x2013;<lpage>57</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3344</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domingo-Gonzalez</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Prince</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Khader</surname> <given-names>S. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Cytokines and chemokines in mycobacterium tuberculosis infection</article-title>. <source>Microbiol. Spectr.</source> <volume>4</volume>, <fpage>1</fpage>&#x2013;<lpage>58</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/microbiolspec.tbtb2-0018-2016</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donovan</surname> <given-names>M. L.</given-names>
</name>
<name>
<surname>Schultz</surname> <given-names>T. E.</given-names>
</name>
<name>
<surname>Duke</surname> <given-names>T. J.</given-names>
</name>
<name>
<surname>Blumenthal</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Type I interferons in the pathogenesis of tuberculosis: Molecular drivers and immunological consequences</article-title>. <source>Front. Immunol.</source> <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01633</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>He</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by ISGylating the phosphatase PTEN</article-title>. <source>Sci. Signal.</source> <volume>16</volume>, <elocation-id>eabm1756</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.abm1756</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Plasma TNFSF13B and TNFSF14 function as inflammatory indicators of severe adenovirus pneumonia in pediatric patients</article-title>. <source>Front. Immunol.</source> <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2020.614781</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haase</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Rink</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Zinc signals and immune function</article-title>. <source>BioFactors</source> <volume>40</volume>, <fpage>27</fpage>&#x2013;<lpage>40</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/biof.1114</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagen</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Aas</surname> <given-names>P. A.</given-names>
</name>
<name>
<surname>Slupphaug</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Off-target responses in the HeLa proteome subsequent to transient plasmid-mediated transfection</article-title>. <source>Biochim. Biophys. Acta - Proteins Proteomics</source> <volume>1854</volume>, <fpage>84</fpage>&#x2013;<lpage>90</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbapap.2014.10.016</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heuvers</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Aerts</surname> <given-names>J. G. J. V.</given-names>
</name>
<name>
<surname>Hegmans</surname> <given-names>J. P.</given-names>
</name>
<name>
<surname>Veltman</surname> <given-names>J. D.</given-names>
</name>
<name>
<surname>Uitterlinden</surname> <given-names>A. G.</given-names>
</name>
<name>
<surname>Ruiter</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>History of tuberculosis as an independent prognostic factor for lung cancer survival</article-title>. <source>Lung Cancer</source> <volume>76</volume>, <fpage>452</fpage>&#x2013;<lpage>456</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lungcan.2011.12.008</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus</article-title>. <source>J. Virol.</source> <volume>82</volume>, <fpage>1665</fpage>&#x2013;<lpage>1678</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/jvi.02113-07</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Tsang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>IFI44L as a forward regulator enhancing host antituberculosis responses</article-title>. <source>J. Immunol. Res.</source> <volume>2021</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/5599408</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Subbannayya</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Humphries</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Skejsol</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Pinto</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Giambelluca</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>UMP-CMP kinase 2 gene expression in macrophages is dependent on the IRF3-IFNAR signaling axis</article-title>. <source>PLoS One</source> <volume>16</volume>, <fpage>1</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0258989</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimmey</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Weiss</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Monte</surname> <given-names>K. J.</given-names>
</name>
<name>
<surname>Lenschow</surname> <given-names>D. J.</given-names>
</name>
<name>
<surname>Stallings</surname> <given-names>C. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The impact of ISGylation during Mycobacterium tuberculosis infection in mice</article-title>. <source>Microbes Infect.</source> <volume>19</volume>, <fpage>249</fpage>&#x2013;<lpage>258</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micinf.2016.12.006</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leisching</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Cole</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Ali</surname> <given-names>A. T.</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>OAS1, OAS2 and OAS3 restrict intracellular M. tb replication and enhance cytokine secretion</article-title>. <source>Int. J. Infect. Dis.</source> <volume>80</volume>, <fpage>S77</fpage>&#x2013;<lpage>S84</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijid.2019.02.029</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leisching</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Pietersen</surname> <given-names>R.-D.</given-names>
</name>
<name>
<surname>Mpongoshe</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Van Heerden</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Van Helden</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wiid</surname> <given-names>I.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>a). <article-title>The host response to a clinical MDR mycobacterial strain cultured in a detergent- free environment: A global transcriptomics approach</article-title>. <source>PLoS One</source> <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0153079</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leisching</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Pietersen</surname> <given-names>R.-D.</given-names>
</name>
<name>
<surname>Wiid</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2016</year>b). <article-title>Virulence, biochemistry, morphology and host-interacting properties of detergent-free cultured mycobacteria: An update</article-title>. <source>Tuberculosis</source> <volume>100</volume>, <fpage>53</fpage>&#x2013;<lpage>60</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tube.2016.07.002</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leisching</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Wiid</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The association of OASL and type I interferons in the pathogenesis and survival of intracellular replicating bacterial species</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>7</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2017.00196</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname> <given-names>M. I.</given-names>
</name>
<name>
<surname>Huber</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source> <volume>15</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madden</surname> <given-names>K.</given-names>
</name>
<name>
<surname>El Hamra</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Berton</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Felker</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Alvarez</surname> <given-names>G. G.</given-names>
</name>
<name>
<surname>Blais</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Mycobacterium tuberculosis infection triggers epigenetic changes that are enriched in a type i IFN signature</article-title>. <source>MicroLife</source> <volume>4</volume>, <fpage>1</fpage>&#x2013;<lpage>18</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/femsml/uqad006</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madhvi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Chegou</surname> <given-names>N. N.</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Increased interferon-induced protein with tetracopeptides (IFITs) reduces mycobacterial growth</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>12</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.828439</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madhvi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Chegou</surname> <given-names>N. N.</given-names>
</name>
<name>
<surname>Tromp</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Van Heerden</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Pietersen</surname> <given-names>R. D.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Distinct host-immune response toward species related intracellular mycobacterial killing: A transcriptomic study</article-title>. <source>Virulence</source> <volume>11</volume>, <fpage>170</fpage>&#x2013;<lpage>182</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/21505594.2020.1726561</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malakhov</surname> <given-names>M. P.</given-names>
</name>
<name>
<surname>Malakhova</surname> <given-names>O. A.</given-names>
</name>
<name>
<surname>Il Kim</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Ritchie</surname> <given-names>K. J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D. E.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>UBP43 (USP18) specifically removes ISG15 from conjugated proteins</article-title>. <source>J. Biol. Chem.</source> <volume>277</volume>, <fpage>9976</fpage>&#x2013;<lpage>9981</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M109078200</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Tagging for protein expression</article-title>. <source>Methods Enzymol</source>. <volume>463</volume>, <fpage>239</fpage>&#x2013;<lpage>258</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0076-6879(09)63016-0</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mears</surname> <given-names>H. V.</given-names>
</name>
<name>
<surname>Sweeney</surname> <given-names>T. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Better together: The role of IFIT protein-protein interactions in the antiviral response</article-title>. <source>J. Gen. Virol.</source> <volume>99</volume>, <fpage>1463</fpage>&#x2013;<lpage>1477</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1099/jgv.0.001149</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Ohsugi</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Yamaguchi</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Ikenoue</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Furukawa</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Decreased expression of interferon-induced protein 2 (IFIT2) by Wnt/&#x3b2;-catenin signaling confers anti-apoptotic properties to colorectal cancer cells</article-title>. <source>Oncotarget</source> <volume>8</volume> (<issue>59</issue>), <fpage>100176</fpage>&#x2013;<lpage>100186</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.22122</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ottenhoff</surname> <given-names>T. H. M.</given-names>
</name>
<name>
<surname>Dass</surname> <given-names>R. H.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>H. E. E.</given-names>
</name>
<name>
<surname>Sahiratmadja</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis</article-title>. <source>PloS One</source> <volume>7</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0045839</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palucci</surname> <given-names>I.</given-names>
</name>
<name>
<surname>Delogu</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Host directed therapies for tuberculosis: futures strategies for an ancient disease</article-title>. <source>Chemotherapy</source> <volume>63</volume>, <fpage>172</fpage>&#x2013;<lpage>180</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000490478</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pidugu</surname> <given-names>V. K.</given-names>
</name>
<name>
<surname>Pidugu</surname> <given-names>H. B.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>T. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Emerging functions of human IFIT proteins in cancer</article-title>. <source>Front. Mol. Biosci.</source> <volume>6</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmolb.2019.00148</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pl&#xfc;ckthun</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding</article-title>. <source>Immunol. Rev.</source> <volume>130</volume>, <fpage>151</fpage>&#x2013;<lpage>188</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1600-065X.1992.tb01525.x</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivera-Serrano</surname> <given-names>E. E.</given-names>
</name>
<name>
<surname>Gizzi</surname> <given-names>A. S.</given-names>
</name>
<name>
<surname>Arnold</surname> <given-names>J. J.</given-names>
</name>
<name>
<surname>Grove</surname> <given-names>T. L.</given-names>
</name>
<name>
<surname>Almo</surname> <given-names>S. C.</given-names>
</name>
<name>
<surname>Cameron</surname> <given-names>C. E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Viperin reveals its true function Efra&#xed;n</article-title>. <source>Physiol. Behav.</source> <volume>176</volume>, <fpage>139</fpage>&#x2013;<lpage>148</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-virology-011720-095930.Viperin</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabaty</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Grosse</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Adryanczyk</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Boiry</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Biaso</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Arnoux</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Detrimental effect of the 6 His C-terminal tag on YedY enzymatic activity and influence of the TAT signal sequence on YedY synthesis</article-title>. <source>BMC Biochem.</source> <volume>14</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1471-2091-14-28</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampath</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Rajamanickam</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Thiruvengadam</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Natarajan</surname> <given-names>A. P.</given-names>
</name>
<name>
<surname>Hissar</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Dhanapal</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis</article-title>. <source>Sci. Rep.</source> <volume>13</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-34530-z</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoggins</surname> <given-names>J. W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Recent advances in antiviral interferon-stimulated gene biology</article-title>. <source>F1000Research</source> <volume>7</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.12688/f1000research.12450.1</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shankar</surname> <given-names>A. H.</given-names>
</name>
<name>
<surname>Prasad</surname> <given-names>A. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Zinc and immune function: the biological basis of altered resistance to infection1</article-title>. <source>Am. J. Clin. Nutri.</source> <volume>68</volume> (<issue>2 Suppl</issue>), <fpage>447S</fpage>&#x2013;<lpage>463S</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ajcn/68.2.447S</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarca</surname> <given-names>A. L.</given-names>
</name>
<name>
<surname>Draghici</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Khatri</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Hassan</surname> <given-names>S. S.</given-names>
</name>
<name>
<surname>Mittal</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>J. S.</given-names>
</name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>A novel signaling pathway impact analysis</article-title>. <source>Bioinformatics</source> <volume>25</volume>, <fpage>75</fpage>&#x2013;<lpage>82</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btn577</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tianzhi.</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Erqiang.</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Shuangbin.</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Meijun.</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Pingfan.</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Zehan.</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title>. <source>Innovation</source> <volume>2</volume>, <elocation-id>100141</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Travar</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Petkovic</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Verhaz</surname> <given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Type I, II, and III interferons: regulating immunity to mycobacterium tuberculosis infection</article-title>. <source>Arch. Immunol. Ther. Exp. (Warsz).</source> <volume>64</volume>, <fpage>19</fpage>&#x2013;<lpage>31</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00005-015-0365-7</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vignesh</surname> <given-names>K. S.</given-names>
</name>
<name>
<surname>Deepe</surname> <given-names>G. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Metallothioneins: Emerging modulators in immunity and infection</article-title>. <source>Int. J. Mol. Sci.</source> <volume>18</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms18102197</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>R.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlas</article-title>. <source>J. Infect.</source> <volume>86</volume>, <fpage>421</fpage>&#x2013;<lpage>438</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jinf.2023.03.020</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="book">
<person-group person-group-type="author">
<collab>WHO</collab>
</person-group> (<year>2024</year>). <source>Global Tuberculosis Report</source>. <publisher-name>World Health Organization</publisher-name>.  Available at: <uri xlink:href="https://www.who.int/publications/i/item/9789240101531">https://www.who.int/publications/i/item/9789240101531</uri>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>IRF1 as a potential biomarker in Mycobacterium tuberculosis infection</article-title>. <source>J. Cell. Mol. Med.</source> <volume>25</volume>, <fpage>7270</fpage>&#x2013;<lpage>7279</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jcmm.16756</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>C. Y.</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>H. Y.</given-names>
</name>
<name>
<surname>Pu</surname> <given-names>C. Y.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>H. C.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C. P.</given-names>
</name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Pulmonary tuberculosis increases the risk of lung cancer</article-title>. <source>Cancer</source> <volume>117</volume>, <fpage>618</fpage>&#x2013;<lpage>624</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cncr.25616</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yadav</surname> <given-names>D. K.</given-names>
</name>
<name>
<surname>Yadav</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Yadav</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Haque</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Tuteja</surname> <given-names>N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>An insight into fusion technology aiding efficient recombinant protein production for functional proteomics</article-title>. <source>Arch. Biochem. Biophys.</source> <volume>612</volume>, <fpage>57</fpage>&#x2013;<lpage>77</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.abb.2016.10.012</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>D. W.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>J. W.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Z.h.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M.x.</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>Y. G.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>D. W.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Downregulation of Metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue</article-title>. <source>Biochim. Biophys. Acta - Mol. Basis Dis.</source> <volume>1822</volume>, <fpage>918</fpage>&#x2013;<lpage>926</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbadis.2012.02.021</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Pinsky</surname> <given-names>P. F.</given-names>
</name>
<name>
<surname>Caporaso</surname> <given-names>N. E.</given-names>
</name>
<name>
<surname>Chatterjee</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Baumgarten</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Langenberg</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial</article-title>. <source>Arch. Intern. Med.</source> <volume>61</volume>, <fpage>515</fpage>&#x2013;<lpage>525</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/archinte.168.21.2326.Lung</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>W.</given-names>
</name>
<name>
<surname>He</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Jiao</surname> <given-names>H. L.</given-names>
</name>
<name>
<surname>He</surname> <given-names>L. Q.</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>D. L.</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>J. J.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway</article-title>. <source>Cancer Lett.</source> <volume>360</volume>, <fpage>68</fpage>&#x2013;<lpage>75</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2015.02.004</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lie</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>B.</given-names>
</name>
<etal/>
</person-group>. (<year>2019</year>). <article-title>Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling</article-title>. <source>J. Infect.</source> <volume>79</volume>, <fpage>262</fpage>&#x2013;<lpage>276</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jinf.2019.06.007</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lie</surname> <given-names>L.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Viperin impairs the innate immune response through the IRAK1-TRAF6-TAK1 axis to promote Mtb infection</article-title>. <source>Sci. Signal.</source> <volume>15</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.abe1621</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>